Freelancing By Fay Bahawalpur

People concern about their physical health and take care of it, but they do not pay attention to their oral health or oral hygiene. Oral hygiene is the process or practice to keep the mouth clean. Taking care of Oral hygiene is just as important as your physical health. Even if you have shiny and whiter teeth, it is necessary to take major steps to keep your teeth healthy. The upper hard surface of your teeth is called enamel, it protects to teeth and helps them to protect from decay. So it is the display of your teeth if your teeth are healthier you will never hide your smile, you will never feel ashamed and as a result, you become more confident. Teeth help us to chew food and enjoying different types of meals. They help us to smile more and worry less. When you talk to someone you notice their teeth first, and you have a good conversation with those who have a good smile. You mostly inspired by someone’s smile at first sight. It is all due to healthier teeth because teeth give shape to our faces. If you have a beautiful smile so it is all off because you have beautiful teeth.

Cavities are the damaged part of your hard surface of teeth, if you do not treat them properly before decaying your teeth then it will causing a dull and steady pain and hence they can tend to tooth loss.  Let’s have some tips which help you to keep your teeth healthier.

1. Brush your teeth regularly

It is a common practice that you should brush your teeth twice a day. It is correspondingly important how you brush your teeth. Moreover doing a bad job of brushing your teeth is nearly as poor as not brushing at all. Take the proper time to brush your teeth. Pay attention when you brush your teeth, brush gently in a circular motion to remove plaque. If plaque stick to your teeth then it leads to early gum disease. People neglect to brush their teeth before going to bed, it is more important to brush your teeth after every meal particularly after having dinner. When we eat food particles remain in our teeth gaps and it leads to a cavity. So take care of your teeth, brush in a proper manner back and forth and in the backside of the teeth, brush your tongue also to have fresh and bacteria-free breathing. Change your brush every 2 or 3 months because it may destroy after 3 months and do not clean your teeth properly and may damage your gums. Also, use an appropriate size of the brush with nylon bristles. By maintaining your brush schedule you may save your teeth from decay.

2. Type of toothpaste you should use

Fluoride is the essential element that helps to strengthen your teeth. Always use those type of toothpaste which has the right amount of fluoride. It helps to harden your surface of tooth and repair tooth in the early stages of decay. According to doctors children under the age of three should use a streak, and children above the age of three should use a pea-sized toothpaste. It also helps to restore the natural color of your teeth. It freshens breathing and reduces plaque. To sustain your oral hygiene, you must use the right amount of toothpaste.

3. Using a mouthwash

You may use mouthwash for fresh breath. If you had a bad breath then you must visit your doctor in order to protect your teeth and before you lose your teeth. People don’t know how mouth wash works. Mouthwash works in three ways, it helps to reduce the amount of acid in your mouth, cleans those areas where the brush cannot reach properly and re-mineralizes your teeth. You may consult your doctor for specific mouthwash.

4. Floss your teeth

People think if they brush daily then they do not need flossing brush is enough for them. But floss is just important as brushing. Floss can help to remove acids produced by bacteria, it can help to remove food particles that are stuck between your teeth. Brush can’t clean properly between the gaps of teeth so flossing is the most appropriate method to clean the teeth from front to back and helps to prevent your teeth from decay.

5. Choose a healthy diet

Every part of the body and our all organs need nutrition to develop and function properly. Teeth also need appropriate amounts of calcium, magnesium, vitamin and phosphorous, etc. you should eat a healthy and proper meals, add green leafy vegetables, fish, eggs, milk, cheese, yogurt in your diet. Calcium and minerals help to restore teeth roots, strengthen gum and repair enamel. Do not use sweets such as candies, pastries, sticky gums in large amount because they stick to your teeth and bacteria begin to grow then bacteria produce acids and your teeth might have a cavity. If you eat sweets then brush your teeth after eating and rinse from water. By choosing a healthy diet you may keep your teeth healthy.

6. Quit Smoking

As you know smoking kills, it affects your health so it also affects your teeth. Smoking can make your teeth yellowish in color you might have bad breath. It effects on saliva production and increases gum diseases. For your health and to prevent your teeth and mouth from disease stop smoking.

7. Visit your dentist Once a month

We all know that prevention is better than cure. You must visit your dentist once a month and check your teeth properly if any cavity is present and you need some treatment then you will know on time and then you may save your teeth from decay or you may prevent from severe tooth-ache. 

8. Drink a lot of water

Water is the best drink for your mouth and overall health. Drinking helps to wash some of the sticky food from your teeth and it also reduces acid in your mouth. So make a habit of drink more it will help to bring a good change in your health.

Final word

Good oral health begins with you. When you start taking care of yourself you see a good change in yourself. Brush your teeth after every meal and twice a day, you must use toothpaste with a specific amount of fluoride. Don’t forget to use a piece of floss and make a habit of using it. Use a specialize mouthwash as per your Dentist recommendations. Choose a healthy diet, a healthy diet contains milk products, leafy vegetables, fish and poultry. Do not smoke as it damages your oral hygiene. Visit your dentist at least once in a month and last but not least drink a lot of water. These tips may help to Stay Healthy.

 Do you want to eat healthily and can't spend much? Well keep reading this article and it is going to help you in one way or another. Who doesn't want to look fit and healthy? Let's talk about some salads you can make by simply using items lying around in your kitchen.

 Taking the correct diet never goes out of style. Wanting to lose weight by eating healthy doesn't mean you can't have fun with your meals. Personally, it is so difficult to keep up with a strict diet when the only thing you love is food. Play around with your salad bowls. Keep adding different veggies, fruits, and anything you like.

 What veggies to include?

You can add whatever veggies you like or depending on the season. Keep changing the ingredients on a daily basis; this would be fun to eat. You should feel attracted to your bowl, funny? No? Well, this is going to help you stay healthy. Let's discuss common veggies that you can easily find.

1. Iceberg lettuce

 Well, iceberg lettuce is a must to have in your green salad. What is the purpose of eating a salad if you don't get that crunch? Got my point? Put in as many green veggies as you like.

2. Cucumber and onion

We are talking about pocket-friendly salad bowls. So, cucumber and onion are going to be in it, obviously. You can easily find these two in your kitchen. I personally like to add onion to a salad for that sour taste. Cucumber is a very good option to put in.

3. Bell pepper

Use this vegetable for that fun, colorful vibe. Use whatever color you like. Cut in rings, square, or chop it as you like. It gives your salad bowl a nice funky touch.

4. Tomato

Some people don't like to eat tomatoes in their salads, well, I am some people. Use tomatoes in slices or dice them. It is up to you. You can add cherry instead if you don't like tomatoes.

5. Black olives

This specific ingredient is my favorite. You can skip or add anything according to your preference. Changing items will give you a new taste every day.

6. Spinach

What would a salad bowl look like without spinach? Bland. Yeah, you heard it right bland. Add in whatever way you want. Dice it, blend it. In any way, it is going to benefit you.

7. Broccoli

If you want to give your salad a fancy look, go ahead and add broccoli. This cute little vegetable has many nutritional benefits. Boil it and it is ready to eat.

8. Coriander

It is kind of the most underrated veggie. I like to add coriander for a colorful dressing. You can use it in many other ways also.

 What everyday Salad dressing ingredients you should have:

Everyone has their own go-to dressing items that are easily available. Match and mix ingredients that are versatile and easy enough to make.

 I like to add things that can be easily made from scratch. The best dressings can be salt, pepper, garlic (chopped or diced), coriander, cheese, or mayonnaise. See, you have all these things in your kitchen. 

 Recipes for your go-to salads:

Easy! All you have to do is mix or stir all your ingredients well and there you go. My go-to recipes are simple and easy on the pocket. So, I can have a variety to eat.

1. Take a bowl. Add cucumber, onion, any green veggie you like, 2-3 olives, tomato, spinach, salt, pepper, 1 green chili ( for that spice flavor), mix all the ingredients and there you go. Happy eating!
2. In a pot. Add iceberg lettuce, tomato, onion, bell pepper ( for a colorful vibe), cucumber, salt, and pepper, and squeeze half lemon. Mix or stir all the items well. In no time, your go-to salad is ready.

 Remember one thing you can mix different veggies and items as per your preference. Eating healthy doesn't mean sticking to boring meals. Go out of your way. Make it fun. Add sweetener if you like. As I said earlier, play with your meals.

I know you are curious to find out what this article holds for you. Are you facing a mental health issue? Well, you don't need to panic; I have been there just like you. We are going to fight this and get over it using some very simple techniques.

 You all know THE ROCK and probably have heard of his wording about this issue if not let's take a look, “I found that with depression, one of the most important things you could realize is that you are not alone. You're not the first to go through it; you are not going to be the last to go through it".  You see, you are not alone. Just hang in there. Let's proceed with our article and see how this is going to help you.

●     Why is it important to take care of your mental health?

 You need to be your own hero to survive. Mental health can destroy your peace and can take away the power of thinking. It is important to look after your emotional health to have a healthy relationship, good work life, personal well-being, and many other aspects. 

 People around us play an important role in our emotional well-being. It is said that people who are socially involved in activities have a healthier life, yet it is difficult for people facing any mental health issues. They find it hard to build any relationship because of their condition which makes it even more poorly. Hence, again it is important to look after your mental health for so many other reasons. 

  Now that we have seen why taking care of your mental health is important. Let's proceed and talk about the tips that help you with it. These techniques may not be the cure but can be helpful in positive thinking.

1. Ask for help when you need 

Letting people know about your emotional health is not enough. Ask for the help you need. Involve your friends, and talk to them about how you feel. Let it all out. If you are struggling, seek professional help as soon as possible. 

2. Change your routine

 If you are a late riser, try to wake up early. Change your daily routine. Involve yourself in other activities that may divert your mind. Start by taking baby steps. Plan more trips with your friends. Go for a walk.

3. Add a workout session

 Working out can be the answer to your situation. It can't solve your problem fully but sweating out is definitely going to redirect your mind. If you don't want to go out, work out at home. Start with small reps as you feel easy. If you think working out alone is difficult, head to the gym with a friend.

4. Eating habits

 Eating a lot is not the correct thing. People who are under stress or anxiety tend to eat more than regularly. Eat in small portions. Take healthy and low-calorie food. Make a schedule of eating and stick to it. 

5. Connect more

 Supportive family and friends are the keys to recovery from mental health problems. If you can't visit daily, talk through messages, video calls, or just calls. Let them know how you feel. Talk about your daily routine.

6. Love yourself

 Facing a mental health condition is not as easy as it looks. Be gentle with yourself. Love yourself. Go with the flow. Don't be so harsh on yourself. Coping with emotional health is a struggle but with a positive mind, you can deal with it. 

7. Learn new things

 We all face good and bad days now and then. But learning from those experiences is important. Learn a new activity to change your mind. It could be anything little or big. If you want to, learn how to paint. Give it a try. You might see if that was the missing spark from your life.

8. Don't be hard on yourself

 If you don't want to get any work done, just Netflix and chill. Give yourself some time. Relax as much as you want. Read a book. Note points you like. Do whatever you feel like doing. Listening to your body and mind is very important when you are battling mental health.

 Mental health is a very sensitive topic. As much as you talk about it. You get to know more about it. Search on the internet about it. You can see people struggling with it and succeeding through the struggle. In short, mental health conditions cannot be cured in one day. It takes time, effort, and most importantly a positive attitude.

 Whether you are going to look after someone having a mental health condition or for yourself. Be patient. Take time. You have to be calm. Make up your mind about what do's and don'ts are going to help you. I hope this article will help you in some ways. 

Ways to stop stress eating and why is it important?

 If you are here it means you are facing stressful eating problems. Let’s not waste our time explaining what stress eating is or what triggers it. This is a common problem almost every person is going through. People tend to eat more when they have stress from work-related issues or family problems. Stress is a main factor that triggers eating habits. Our circumstances or situations from daily life also trigger stress and anxiety which makes us emotional eaters. Stress sometimes comes from within, asking for a raise at work, confronting a friend, or the idea of being perfect at everything. These all conditions trip stress and anxiety.

Positive and negative stress

Both good and bad situations can give stress. If I am joining a new job that is good in all ways but still feeling stressed and anxious it is the phase of that changing. Change always brings anxiety and stress with it. Adapting to a new place, and understanding new work or people is always stressful. If we talk about a bad situation, confronting someone for something they did to you also gives you tension. It also triggers stress, so both positive and negative situations create tension.

How eating helps with stress?

 Some people master this art of controlling their stress in front of others and acting cool. You learn this difficult way and it takes too much courage and time. The only problem which is not so easy to let go of is Stress Eating. You might have heard of the term COMFORT FOOD; it is called this because of a reason. People have different eating habits and favorite foods. Food that can calm them, relax them, and make them forget about their problems is called their Comfort food. Having too much of this can turn out to be unhealthy.

 Most people feel comfortable after eating a plate full of pasta or a big cup of ice cream. Everyone has different emotional eating habits. Stress eating is a common thing but eating too much can come between your wellness and health. I also face stress eating issues every now and then, mostly craving something sweet. This after some time affects my health and weight. Stress eating is normal, and not knowing when to stop is not normal.

 When stress eating becomes habitual during an emotional period of time it can cause severe problems for you. That is the time you need to understand your body and what it is asking for. Now, let’s take a look at ways that can help you to stop from overeating:

1.         A glass of water:

The easiest and simplest way to help you without spending a single penny is a Glass of water. We don’t drink as much water anyway. So drinking water can calm you down and fill that space in your stomach. It is an old trick that works for me by the way.

2.         Write it down:

Sometimes you can’t tell everyone what you are going through. Just grab a pen and book, and start writing it down. What you are going through, what is affecting you, your feelings, emotions, etc. will help you to calm yourself down. We emotionally overshare with people sometimes and regret it later. Well, writing it in a book will not make you regret it. Start making bullet points of the things which cause stress and anxiety. Read them when you feel good. Eating a plate full of pasta might not help later but this will.

3.         Go for a walk:

If you are feeling stressed or anxious, just excuse yourself and take a walk. Leaving a specific area can help you to calm your nerves down. Breathing in the fresh air will help you to think clearly. This will also help you to relax and feel light. When the urge of eating junk, sweet, or fast food hits, get up and go for a walk or run. 

 If you like to work out, do that instead. Hit your gym or any home cardio you are interested in. Eating will only raise your calories and weight. Working out will help a long way.

4.         Talk to someone:

Feel stressed out and want to eat junk? Well, try talking to someone about your condition. Any person you are comfortable with and you know will understand your emotions and feelings. Try talking to them at that time. They might be able to give you a solution you didn’t think of. Eating in this condition you will only put up your weight.

5.         Watch your Comfort show:

I know some of you would like to know what a comfort show is, Right? Well in my dictionary any show that can calm my nerves when I am stressing out is my comfort show. Far better than having Comfort food. Watch any drama, serial, show, movie, or season that can divert your attention. You might learn something or maybe you can have a new comfort show at the end.

 Lastly, these are some ways that can divert your attention for that specific time. If you face this problem every now and then you need to consult a professional. These may not help you to overcome your stress or anxiety but will calm you for some time. Well, indulging in stress eating once in a blue moon is okay, but doing this regularly is not healthy. The mentioned ways can help you to control stress eating and some may be beneficial for your health as well.

If you are here reading this that means you are well aware of the word BULLYING and its sensitivity. So, let's proceed with the effects of it. Someone who says he or she has never faced bullying in their life. Well, that is something I am not sure about. I, myself, have faced bullying in one way or other in my childhood. Being harassed can affect your mental, physical, and emotional health.

Teenagers who face harassment in any way seem to be more depressed and have anxiety and low self-esteem. Bullying is a serious matter and should be taken thoughtfully. Bullies are at higher risk of being anti-social. Youngsters who have tormented others and been forced to bear harassment, experience the most serious impacts. They're at a more serious gamble for mental and social issues.

How to proceed towards the problem of Bullying

Talking to your child about their experience and letting them show their emotions is all they need. Don't try to treat it as an unimportant event. Let your child speak and tell you how they feel. Sometimes only talking about this issue is not enough. Parents need to take some steps for the well-being of their children.

  Also, encouraging your child to speak up about the situation can give them strength. Make them feel at home. Let them talk about the stuff they have gone through. This might not help with overcoming the trauma, but it will give them the courage to move forward in life. 

 Most children don't like to talk about the stress or harassment they have gone through. Try to pay close attention to their behavior. Teenagers going through this phase mostly show aggression, hyper behavior, eating disorder, lack of interest in studies, and antisocial attitude.

Effects on Mental health

Teenagers facing bullying trauma have a very severe effect on their mental health. They show some very serious symptoms.

1. They may act clingy all the time. Change in their attitude leads to mental health problems.
2. Eating disorders can be the cause of bullying. Teenagers’ not paying attention to their eating schedule or eating more than normal is an alarming situation.
3. Harassment affects one's sleeping schedule also. Taking long naps or no sleep at all upsets their mental health. 
4.  Less academic achievement or zero interest in extracurricular activities indicates mental health issues.
5. Getting into unnecessary fights over little things. Showing an aggressive attitude every now and then. The problems they don't share result in aggression. 
6. Prefer staying alone in presence of their friends. Anyone who is bullied in any way blames people around them for not understanding their condition.

 Teachers and parents play an essential role in any teenager's life. Giving them some of your time can be a big thing for them. Trauma that is not discussed becomes a painful memory with time. It affects their childhood, studies, and whatnot. 

 These are some of the symptoms that children show visibly. Whereas, anxiety, low self-esteem, anti-social behavior, stress, and loneliness are signs that are not shown very visibly. Paying close attention to your child can help you to find out their problem. Talking to them as their friend can help them cope with the trauma.

 Bullying not only makes those years difficult for a child but also gives a long life trauma.  Other than this, youth and teenagers who witness bullying and say nothing can have an expanded possibility of feeling restless, discouraged, or guilty.

 Talking about Bullying

 This might be a milestone kind of step but talking about it in public is all victims need. Breaking these barriers will help the youth to stand up against their bullies. One step will save many lives. Keeping it a secret or getting scared will only worsen the mental health of your child. 

 Bullying affects everyone sadly, not only the victim. The future of the person getting bullied gets tarnished badly. Teenagers might not have the power to stand with confidence in the future against any bad thing happening. It leads to severe mental illness as well as affects future relationships. 

 Whenever you suspect a slight change in your child's behavior, don't wait for them to express it. Ask away, give them their space. Children don't share until or unless they feel safe with you. Take small steps to ensure your child's safety. Be a guide for them. Most importantly start the conversation in a friendly way, be their friend for some time. 

 Understanding your child is the most important thing you can do at that time. Seek help from professionals. Bullying can leave some harsh memories in your child's mind if not treated correctly. This may seem like a small thing but it can affect their mental health in a bad way.

The report turns the spotlight on the major challenges faced by the key players in the global market and the growth strategies currently adopted by them. The report is a granular assessment of this particular business sphere and entirely covers the dynamic competitive landscape of the market. The document offers key insights into the market positions of these players alongside their gross earnings. Furthermore, it elaborates on each of the market segments, with detailed scrutiny of the development scope and competitive scenario of the regional fragments of the market.

The latest study is inclusive of an in-depth analysis of the economic status of the Nutrigenomics market and examines the most important regions constituting the global market. It further details on the most lucrative and growth-oriented regions, top market rivals, diversified product types, and a large number of end-use industries.

To get a sample copy of the latest market report, visit

https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html

Key factors affecting the growth of the Nutrigenomics market:

Geographical Overview:

The latest report broadly categorizes the Nutrigenomics market into several geographical terrains, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The study is inclusive of essential information relevant to each region in this broad industry segment, along with the key drivers of the regional market growth.

The report further estimates the revenue accumulated by these regions over the forecast period.

Competitive Hierarchy:

The latest research report studies the major market players, their regional presence, industry share, and production facilities.

The report offers significant data pertaining to these market competitors’ company profiles, product types, and application outlook.

Moreover, the pricing models and gross margins of these industry majors have also been mentioned in the report.

Additional parameters of the Nutrigenomics market report:

The latest research study endows the reader with a comprehensive analysis of the product types of the Nutrigenomics market, categorizing the relevant information into the market share, production growth rate, and profit valuation of each product type. The study focuses on the wide-ranging application landscape of the market, segmenting it into the market share, estimated growth rate, and the forecast product demand for each application type.

Additional Insights:

The market concentration rate and processing rate of raw materials have also been conscripted in the report.

The report contains an assessment of the current price trends, as well as the factors influencing the global market size.

It throws light on the significant marketing strategies implemented by the eminent players in the industry.

Vital data and information concerning the producers, distributors, and downstream buyers involved in the global market, as well as the cost structure analysis and market mechanism, form the important elements of this report.

 Research objectives:

The Nutrigenomics market report studies the worldwide market consumption rate in terms of value and volume.

It identifies the various sub-segments of the market structure.

It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline.

The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges.

Furthermore, the report underpins the strategic developments occurring in the Nutrigenomics market, such as expansions, mergers & acquisitions, agreements, as well as new product launches.

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/nutrigenomics-market.html

You may also be interested in the following titles:

1.      Oral Proteins and Peptides Market, 2022-2035

2.      Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

#NutrigenomicsMarket #NutrigenomicsMarketsize #NutrigenomicsMarketgrowth #NutrigenomicsMarketshare

The report turns the spotlight on the major challenges faced by the key players in the global market and the growth strategies currently adopted by them. The report is a granular assessment of this particular business sphere and entirely covers the dynamic competitive landscape of the market. The document offers key insights into the market positions of these players alongside their gross earnings. Furthermore, it elaborates on each of the market segments, with detailed scrutiny of the development scope and competitive scenario of the regional fragments of the market.

The latest study is inclusive of an in-depth analysis of the economic status of the Nutrigenomics market and examines the most important regions constituting the global market. It further details on the most lucrative and growth-oriented regions, top market rivals, diversified product types, and a large number of end-use industries.

To get a sample copy of the latest market report, visit

https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html

Key factors affecting the growth of the Nutrigenomics market:

Geographical Overview:

The latest report broadly categorizes the Nutrigenomics market into several geographical terrains, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The study is inclusive of essential information relevant to each region in this broad industry segment, along with the key drivers of the regional market growth.

The report further estimates the revenue accumulated by these regions over the forecast period.

Competitive Hierarchy:

The latest research report studies the major market players, their regional presence, industry share, and production facilities.

The report offers significant data pertaining to these market competitors’ company profiles, product types, and application outlook.

Moreover, the pricing models and gross margins of these industry majors have also been mentioned in the report.

Additional parameters of the Nutrigenomics market report:

The latest research study endows the reader with a comprehensive analysis of the product types of the Nutrigenomics market, categorizing the relevant information into the market share, production growth rate, and profit valuation of each product type. The study focuses on the wide-ranging application landscape of the market, segmenting it into the market share, estimated growth rate, and the forecast product demand for each application type.

Additional Insights:

The market concentration rate and processing rate of raw materials have also been conscripted in the report.

The report contains an assessment of the current price trends, as well as the factors influencing the global market size.

It throws light on the significant marketing strategies implemented by the eminent players in the industry.

Vital data and information concerning the producers, distributors, and downstream buyers involved in the global market, as well as the cost structure analysis and market mechanism, form the important elements of this report.

 Research objectives:

The Nutrigenomics market report studies the worldwide market consumption rate in terms of value and volume.

It identifies the various sub-segments of the market structure.

It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline.

The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges.

Furthermore, the report underpins the strategic developments occurring in the Nutrigenomics market, such as expansions, mergers & acquisitions, agreements, as well as new product launches.

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/nutrigenomics-market.html

You may also be interested in the following titles:

1.      Oral Proteins and Peptides Market, 2022-2035

2.      Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

#NutrigenomicsMarket #NutrigenomicsMarketsize #NutrigenomicsMarketgrowth #NutrigenomicsMarketshare

Roots Analysis is pleased to announce the publication of its recent study, titled, “Monkeypox Market: Focus on Therapeutics, Vaccines and Diagnostic Kits, 2023-2035”

The study features an extensive study of the current market landscape and future opportunity for the players focused on the development of monkeypox therapeutics, vaccines and diagnostic kits.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/monkeypox-treatment-market/request-sample.html

Amongst other elements, the report features:

§  A general introduction to monkeypox virus, along with information on signs and symptoms of the disease, history of monkeypox outbreaks and details on transmission of disease from animals to humans and humans to humans.

§  A detailed assessment of the current market landscape of monkeypox therapeutics / vaccines that are approved / under development, based on several relevant parameters.

§  A detailed assessment of the current market landscape of monkeypox diagnostic kits, based on several relevant parameters.

§  A product competitiveness analysis of the monkeypox diagnostic kits, based on supplier power and product competitiveness.

§  Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in monkeypox therapeutics / vaccines and diagnostic kits domain.

§  An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022 (till October).

§  An in-depth analysis on various grants, received since the year 2003, by players engaged in this field.

§  A detailed analysis of more than 200 peer-reviewed, scientific articles related to research on monkeypox therapeutics / vaccines and diagnostic kits, during the period of 2018-2022 (till September).

§  A qualitative analysis to understand the five competitive forces under an insightful Porter's Five Forces framework.

§  More than 165 diagnostic kits are currently available in the market for the detection of monkeypox virus; these kits utilize various detection methods for monkeypox diagnosis

§  Presently, more than 25 therapeutics and vaccines are either marketed or under preclinical / clinical development for the treatment and prevention of monkeypox disease.

§  A detailed market forecast for monkeypox therapeutics / vaccines and diagnostic kits, featuring analysis of the current and projected future opportunity across key market segments (listed below):

§  Type of Product

§  Therapeutics

§  Vaccines

§  Developer

§  Bavarian Nordic

§  Emergent BioSolutions

§  KM Biologics

§  SIGA Technologies

§  Type of Kit

§  Polymerase Chain Reaction (PCR) Detection Kits

§  Antigen Detection Kits

§  Antibody Detection Kits

§  Type of End User

§  Hospitals and Clinics

§  Diagnostic Laboratories

§  Other End Users

§  Key Geographical Regions

§  North America (US and Canada)

§  Europe (UK, France, Germany, Spain, Italy, Rest of EU)

§  Asia-Pacific (Japan and Australia)

§  Rest of the World

§  Transcripts of interviews held with the following senior level representatives of stakeholder companies:

§  Willy Tozoke Laou Man Cheong (Business Director, Hunan Runmei Gene Technology)

§  John W Sharkey (Vice President, Business Development, GeoVax)

§  Horace Lee (Sales Manager, Firegene)

§  Alan Yu (Sales Manager, Hangzhou Testsea Biotechnology)

Key companies covered in the report

§  Bavarian Nordic

§  Emergent BioSolutions

§  ACON Laboratories

§  altona Diagnostics

§  DNA Software

§  Elabscience

§  Goldsite Diagnostics

§  Hangzhou Testsea Biotechnology

§  Jiangsu Bioperfectus Technologies

§  Lansion Biotechnology

For additional details, please visit https://www.rootsanalysis.com/reports/monkeypox-treatment-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

HYPERACIDITY

These days, due to undesirable eating habits and way of life, numerous individuals are fronting problems with acidity like gas. Hyperacidity is key reason for individuals that are meeting gas problems. This occurs in all types of people like in all community or all ages. The stomach is responsible for secreting a digestive juice i.e Hydrochloric Acid, that breaking down the food particles in small particles and to help assimilation. When extreme hydrochloric acid within the stomach, this state is called Hyperacidity. Moreover, it is also known as gastritis or acid reflux disease, The inflammation occurs in the lining of stomach that's triggered by infection caused by bacteria or habits, like consumption of alcohol. Gastritis may happen all of a sudden i.e acute or show up gradually over time i.e chronic and in a few serious cases may lead genuine stomach related ailments like ulcers and indeed stomach cancer.

Symptoms : Burning of Heart, Chest and Throat, acrid taste within the mouth or bitter taste, pain in chest, dry cough and asthma

Adults and children can endure from acidity at least once in their lifetimes. Individuals who devour as well much coffee, alcoholic drinks, and carbonated refreshments on an everyday basis are at chance of creating hyperacidity more frequently than regular. Taking food that are oily and spicy all the time can to upset your stomach lining and resulting in gastritis. Certain medication like ibuprofen and aspirin also increase the risk. 

Hyperacidity is associated to indigestion and can be treated by OTC antacids. It is additionally suggested that you simply avoid taking certain foods which may aggravate the stomach. Your specialist may recommend other medications like h-2 receptor antagonist and proton PPIs for more serious sfferer.

GERD

Gastroesophageal reflux disease is a condition caused by reflux of gastric matter through lower esophageal sphincter into oropharynx or esophagus which causes injury to tissues of esophagus. Many people face heartburn associated with non-pathological gastric reflux once per hour due to retrograde movement of gastric matter into esophagus. While the pathologic gastric reflux shows many symptoms and pathologic changes in esophagus. Episodes of pathologic GERD are longer and more frequent and can occur in day or night. They result in mucosal damage of esophagus, inflammation and chronic injuries. GERD can be developed by conditions which complement each other which enhance the stay time of refluxed acid in esophagus to pathologic condition. Failure in esophageal acid clearance, decreased relaxation of lower esophageal sphincter, impaired resistance in tissues, delayed in gastric emptying and decreased saliva secretion are some mechanisms leads to pathologic GERD. Patients with mild GERD usually shows increased esophageal acid exposure during postprandial period. Esophageal acid exposure is increased by impaired clearance of acid, it can use to determine the severity and frequency of symptoms and extend of mucosal tissue injury. 

Lower esophageal sphincter is ring of thick circular smooth muscles which causes high pressure zone of about 2-4 cm in gastroesophageal junction to prevent the interference of gastric material into esophagus. Improper function of LES leads to inability of anti-reflux barriers. Pressure of LES is increased in night time and after meal but lower in daytime. There are many substances that can decrease LES pressure includes glucagon, secretin, progesterone, theophylline, serotonin and some drugs like calcium channel blockers, barbiturates alpha adrenergic agonists, some foods and beverages also contribute in it includes chocolate, peppermint, alcohol etc. many studies show that obesity assure the causal relationship with GERD and its complications like esophagitis and esophageal adrenocarcinoma. It has shown symptoms of GERD increase in people who are obese but have normal BMI. If consider separately then abdominal obesity explains major association with GERD. Some studies revealed in Pakistan GERD is more common in urban areas. During studies of lifestyle factors related to GERD it has been shown that usual patients of GERD in Pakistan are those who have increased body weight, have habit of taking snacks in midnight and skipping breakfast, don’t exercise more than 30 mins, have inadequate sleep cycle, have supper before two hours of sleep and have smoke. 

PEPTIC ULCER

the inside open sores which start to develop in the stomach lining and occurs at the small intestine on its upper portion is known as peptic ulcer.

Types:  

peptic ulcers are of two types 

1) gastric ulcer

2) duodenal ulcer

· Gastric ulcer:

its occurence is inside the stomach.

· Duodenal ulcer:

its occurrence is on the portion which is located at the upper side of tbe small intestine which is duodenum.

causes:

· H. pylori bacterium:

when H.pylori bacteria starts to stick in the digestive tract on the mucosal lining of stomach through which irritation or inflammation starts to occur and the lining which protect the stomach breaks down and cause ulcers because for the digestion of food our stomach contains acid and when this protective layer break down the acid will harm your stomach.

medicines:

· Medicines

 like NSAIDS (ibuprofen, naproxen, aspirin) can be the reason for inflammation in the stomach lining. SSRIs and anticoagulants.

foods which are spicy can worsen the peptic ulcers.

· Tumours:

the occurrence of tumors in duodenum, pancreas or stomach which can be malignant or benign can cause peptic ulcer.

symptoms:

· heart burn

· nausea

· vomiting, blood in vomiting

· bloating

· belching

· stomach pain like burning

· loss of weight

· stools will be dark

· indigestion

Complications Of Peptic Ulcer:

· when the ulcers are not treated for a long time the situation will become worse day by day.

· bleeding internally:

if the internal bleeding starts there will be the loss of blood and also the stools with black color can worse the condition and the sign of loss of blood.

· tissue scar:

when there is any injury occurs inside the lining of stomach the thick tissue will develop which can cause difficulty in digestion of food and it can occur due to vomiting.

· perforation:

in the small intestine lining of stomach, the hole starts to develop which cause infection and the sever pain in abdominal is the sign of perforated ulcer.

· Refractory ulcer:

the ulcer which is not treated by any of the medication or the treatment is called as refractory ulcer and this ulcer cause due to some reasons

Ø there is excessively production of acid in stomach

Ø the presence bacteria, but not the H.pylori bacteria that means other than this bacteria.

Ø disease such as crohn's disease or the cancer of stomach.

How to prevent peptic ulcer:

· to avoid from infections and bacteria wash your hand properly.

· dont take alcohol and also avoid smoking.

· if there is need to take NSAIDS than limit these medications and instead of this you can take acetaminophen. and if you are taking NSAID than take the medicine which can lowers the acid amount in stomach such as PPIs and H2 blockers.

· drink clean water and east cooked food.

· manage your stress because high level of stress can worse peptic ulcers.

· avoid spicy foods and maintain a healty diet and add fruits and vegetables in your diet.

Diagnostic test for peptic ulcer:

· endoscopy upper

· upper GI series

TREATMENT 

PROTON PUMP INHIBITORS

PPI’s used to cure symptoms of  gastroesophageal reflux disease (GERD) or acid reflux to reduce acidity or acid secretion in stomach. In this condition food or liquid moves up from the stomach to the esophagus. It is used in the treatment of gastric or duodenal ulcer. They are commonly available as capsules or tablets and taken 30 minutes before the first meal of the day.

Types of PPIS

· Lansoprazole

· Esomeprazole

· Omeprazole

· Pantoprazole

· Rabeprazole 

The main goals of antacids are:

Alleviating pain sensations

Relieving pylorospasms

Avoiding corrosion by highly acidic chime.

METHODS & MATERIALS:

The questionnaire was developed by a group of Pharmacy students, who had especial knowledge about the management diagnosis and treatment of Hyperacidity. The questions were designed to identify the sensations & symptoms experienced by the patients. We used the software of Microsoft to develop the questionnaire. The subjects were specifically above 13 so that a specific age scale could be maintained.  Occurrence to factors that are known to provoke hyperacidity,  for example: meals, lifting, spicy food, taking any drug was taking into considerance. For each sensation response was assessed over a scale of positive, negative or neutral . On the basis of pathophysiology and significance for GERD more focus was placed over the predominance of the disease. The provocative factors were given negative values over a score assessed through the bar chart. The results were based over the statistical analysis through the score stated in the bar chart.

TESTING QUESTIONNAIRE: 

Questions designed were built on the study of several articles. The first section of questionnaire was based on the symptoms occurring by meals or any other factor. The occurrence of the  heart burn, acid regurgitation, degree of pain etc. Also how did the subject got it relieved weatherly antacids or any other remedy. The questions ahead were the branch of the previous questions as the next question was linked with the previous one, designed to assess the influence of hyperacidity on the scale from highest to lowest. Other questions were also designed to assess the comorbidities faced by the patient to assess the high specificity reasoning for the occurrence of hyperacidity. For better assessment & feasibility questions were also designed according to the treatment usually subject take for the treatment weather is it a natural remedy, a medication, or nothing at all. Statistical analysis was calculated so that the results could be summarised accordingly & reliability of each question could be maintained.

RESULT:

In total, 46 people participated in a 2 day study survey for hyperacidity. Among which most were students ages were between 18-25 who basically knew what hyperacidity was. 65.2% correctly described the symptoms while other mixed up the symptoms with other gastrointestinal diseases or chest pain. 32.8% suffered hyperacidity with no specific time while 30.4% suffered with hyperacidity after the intake of food, which 51% took aspirin to relieve or in consideration with natural remedies mostly took cold milk, concluding that hyperacidity is a disease which should be given proper attention. 

DISCUSSION:

Hence, in this study we addressed various aspects of hyperacidity. We provided a series of questions related to self/ natural diagnosis and remedies, symptoms, and treatment for patients with hyperacidity, founded on the responses to a questionnaire-based survey we concluded that more than half population don’t visit physician when suffering from hyperacidity rather self-medicate or use natural remedies. Majority knew what hyperacidity was and didn’t give serious attention towards the disease. Most of them labelled it as a disease but not a severe one which could be relived just by aspirin or even cold milk (acc to responses). 

These days, due to undesirable eating habits and way of life, many individuals are fronting issues with acidity. Hyperacidity is main reason for individuals are meeting gas problems. Hyperacidity is also acknowledged as gastritis or acid reflux which is the inflammation of the linning of stomach that is generally caused by bacterial infection or different habits such as consumption of alcohol or even stress. Eating a hefty meal and even back lying or bending from the waist. Eating at the time of bed or snacking certain foods, such as chocolates, citrus, garlic, tomato, mint, onions, or spicy or fatty foods. Drinking beverages like alcohol, carbonated drinks, coffee, or tea may cause hyperacidity. A popular treatment approach for gastric hyperacidity is the use of proton-pump inhibitors. 
for making symptoms easier:
Avoid going to bed with a full stomach. Eat your meals as a minimum 2 to 3 hours before lying down. Avoid overeating. Eat lesser portions at suppertimes, or try to eat four to five small meals in its place of three big meals. Eat calmly and slowly. Take your time to eat. Reduce triggers of heartburn.

Roots Analysis is pleased to announce the publication of its recent study, titled “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings.

The report features an extensive study of the current market landscape and future potential of the novel antibody therapies market. Currently, majority of the radioimmunoconjugates are in clinical stages of development; more than 50% of the microbial immunotoxin candidates are administrated intravenously. The study features an in-depth analysis, highlighting the novel antibody therapies developers.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/novel-antibody-therapies-market/request-sample.html

Amongst other elements, the report features the following:

§  A detailed review of the current market landscape of different types of novel antibody therapies, namely Immunocytokines, immunotoxins and radioisotope immunoconjugates based on several relevant parameters.

§  Elaborate profiles of the key players engaged in the development of novel antibody therapies

§  An in-depth analysis of completed, ongoing and planned clinical studies of various novel antibody therapies

§  A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies

§  An insightful analysis of the patents filed / granted for novel antibody therapies, since 2017

§  An analysis of several partnerships and collaborations inked by novel antibodies players since 2018, based on several relevant parameters.

§  An analysis of big pharma players engaged in the field of novel antibody therapy, featuring various insightful representations

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Target disease Indication(s)

§  Acute Myeloid Leukemia

§  Advanced / Metastatic soft-tissue sarcoma

§  Melanoma

§  Diffuse Large B-cell Lymphoma

§  Bladder Cancer

§  Prostate Cancer

§  Graft-versus-host disease

§  Type of Novel Antibody

§  Immunocytokines

§  Immunotoxins

§  Radioisotope immunoconjugates

§  Type of Therapy

§  Combination Therapy

§  Monotherapy

§  Route of Administration

§  Intravenous

§  Intravesical

§  Intratumoral

§  Geographical Region

§  North America

§  Europe

§  Asia-Pacific

Key companies covered in the report

§  Actinium Pharmaceuticals

§  Molecular Templates

§  Philogen

§  Roche

§  Seagen

§  Sesen bio

§  Telix Pharmaceuticals

§  Y-mAbs Therapeutics

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis is pleased to announce the publication of its recent study, titled “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings.

The report features an extensive study of the current market landscape and future potential of the novel antibody therapies market. Currently, majority of the radioimmunoconjugates are in clinical stages of development; more than 50% of the microbial immunotoxin candidates are administrated intravenously. The study features an in-depth analysis, highlighting the novel antibody therapies developers.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/novel-antibody-therapies-market/request-sample.html

Amongst other elements, the report features the following:

§  A detailed review of the current market landscape of different types of novel antibody therapies, namely Immunocytokines, immunotoxins and radioisotope immunoconjugates based on several relevant parameters.

§  Elaborate profiles of the key players engaged in the development of novel antibody therapies

§  An in-depth analysis of completed, ongoing and planned clinical studies of various novel antibody therapies

§  A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies

§  An insightful analysis of the patents filed / granted for novel antibody therapies, since 2017

§  An analysis of several partnerships and collaborations inked by novel antibodies players since 2018, based on several relevant parameters.

§  An analysis of big pharma players engaged in the field of novel antibody therapy, featuring various insightful representations

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Target disease Indication(s)

§  Acute Myeloid Leukemia

§  Advanced / Metastatic soft-tissue sarcoma

§  Melanoma

§  Diffuse Large B-cell Lymphoma

§  Bladder Cancer

§  Prostate Cancer

§  Graft-versus-host disease

§  Type of Novel Antibody

§  Immunocytokines

§  Immunotoxins

§  Radioisotope immunoconjugates

§  Type of Therapy

§  Combination Therapy

§  Monotherapy

§  Route of Administration

§  Intravenous

§  Intravesical

§  Intratumoral

§  Geographical Region

§  North America

§  Europe

§  Asia-Pacific

Key companies covered in the report

§  Actinium Pharmaceuticals

§  Molecular Templates

§  Philogen

§  Roche

§  Seagen

§  Sesen bio

§  Telix Pharmaceuticals

§  Y-mAbs Therapeutics

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis is pleased to announce the publication of its recent study, titled, “Rare Kidney Disorders Market, 2022–2035”. Over 25 total pipeline candidates are available in the market across various geographical regions. Of these, 43% have been approved for the treatment of cystinosis, Fabry disease and lupus nephritis. Further, majority of the approved / under development drugs (47%) are designed for delivery via oral route.

The report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney disorders market, over the next decade.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/rare-kidney-diseases-market/request-sample.html

The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

§  A detailed executive summary of key insights captured during our research. It offers a high-level view on the current state of rare kidney disorders market and its likely evolution in the mid to long term.

§  A brief introduction to various aspects of rare kidney disorders. It includes a detailed discussion on the historical evolution and factors contributing to the treatment of rare kidney disorders. Further, it highlights various prominent target indications associated with rare kidney disorders, application of omics technology and its future perspectives.

§  A detailed overview of the current market landscape of more than 125  drug candidates that are either approved or currently under development for the treatment of various rare kidney disorders, based on several relevant parameters, such as phase of development (approved, registration, phase III, phase II, phase I, pre-clinical and discovery), target molecule (complement component 5 (C5), complement component 3 (C3), a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLyS), Complement Factor B, and others), route of administration (oral, intravenous, subcutaneous, and others), and target indication (complement 3 glomerulopathy (C3G), focal segmental glomerular sclerosis (FSGS), IgA nephropathy (IgAN), lupus nephritis (LN), membranous nephropathy (MN)), type of molecule (biologics and small molecules), and type of biologic (monoclonal antibody (mAb), hormone, recombinant protein, enzyme replacement therapy (ERT), gene therapy, small interfering ribonucleic acid (siRNA) molecule and others). In addition, it presents details of the companies engaged in the development of drugs targeting rare kidney disorders, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, and most active players.

§  Elaborate profiles of approved and clinical stage drugs indicated for rare kidney disorders (phase II / III or above). Each profile features an overview of the drug developer, clinical trial information related to the drug, clinical trial results, and estimated sales revenues (if available).

§  A detailed competitiveness analysis of companies engaged in the development of rare kidney disorders targeting drugs, based on their developer strength (in terms of years of experience), portfolio strength (in terms of number of drugs developed), and portfolio diversity (in terms of phase of development, target indication, and drug designation).

§  An in-depth analysis of the various collaborations and partnerships that have been inked by players engaged in the development of drugs targeting various rare kidney disorders since 2017, based on several relevant parameters, such as year of partnership, type of partnership, focus area, type of partner and regional distribution of partnerships.

§  An analysis of the funding and investments made within the domain, during the period 2016-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, debt financing, grants, IPOs and other offerings), leading players (in terms of amount invested) and key investors (in terms of number of funding instances).

§  A detailed clinical trial analysis of ongoing clinical studies for the evaluation of various drug candidates targeting rare kidney disorders, based on several relevant parameters, such as trial registration year, current trial status, phase of development, key target indications, patient age, study design and key geographical regions. 

§  A detailed analysis of the clinical and commercial attractiveness for drugs targeting rare kidney disorders, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.

§  A case study highlighting the companies engaged in offering kidney care services, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters and target indication.

The financial opportunity within the rare kidney disorders market has been analysed across the following segments:

§  Type of Molecule

§  Small Molecules

§  Biologics

§  Route of Administration

§  Oral Delivery

§  Intravenous Delivery

§  Subcutaneous Delivery

§  Other Delivery Routes

§  Target Indications

§  Alport Syndrome

§  Atypical Hemolytic Uremic Syndrome

§  C3 glomerulopathy

§  Cystinosis

§  Cystinuria

§  Dense Deposit Disease

§  distal Renal Tubular Acidosis

§  Fabry disease

§  IgA nephropathy

§  Lupus Nephritis

§  Refractory Gout

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

§  Rest of the World

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/rare-kidney-diseases-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “Nutrigenomics Market, 2022 - 2035” report to its list of offerings.

The advances in the field of genomic data collection and analysis have paved a path for the novel concept of nutrigenomics, the science studying the relationship between human genome, nutrition and health. At present, more than 100 companies are engaged in providing various types of nutrigenomic test / services, including those focused on nutritional deficiency, food intolerance / sensitivity, nutrient metabolism, disease risk assessment, diet customization, lifestyle management and weight management, worldwide. Although the field of nutritional genomics is still in a nascent stage, it is a moving at a very fast-pace and is believed to have the potential to lay the foundation for personalized nutrition offerings.

Key Market Insights

Over 100 companies claim to offer various nutrigenomics tools / services

Majority of the firms (94%) engaged in this domain are small players, followed by mid-sized companies (5%) and large firms (1%). Additionally, around 50% of the stakeholders were established post 2015. It is also worth mentioning that over 40% of the total players are based in North America; within this region, the US emerged as the most prominent hub, featuring the presence of the maximum number of players.

~85% firms in this domain provide nutrigenomics tests to identify nutritional deficiencies
Most of the companies engaged in this domain claim to have the required expertise to offer diet customization and lifestyle management services. In addition, of the total, over 55% of the stakeholders provide the provision of at-home sample collection to their clients.

About 135 articles related to nutrigenomics have been published in reputed scientific journals, since 2019

It is worth mentioning that more than 75% of the articles focused on nutrigenomics were published post-2019. Popular journals that have published multiple articles include Frontiers in Immunology, Cancers, Cells and Frontiers in Nutrition.

North America and Europe are anticipated to capture over 70% of the market share, by 2035

The nutrigenomics market in Asia-Pacific is likely to grow at a relatively faster pace (12.9%) in the long term. Further, in 2035, the nutrigenomics market for saliva sample is expected to capture the majority share (~75%) of the overall market.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html

Key Questions Answered

§  Who are the key players engaged in the nutrigenomics market?

§  What is the relative competitiveness of nutrigenomics focused companies?

§  What is the focus area of the ongoing research activity related to nutrigenomics?

§  What are the key factors that are likely to influence the evolution of this market?

§  How is the current and future market opportunity likely to be distributed across key segments?

The financial opportunity associated with the nutrigenomics market has been analyzed across the following segments:

§  Type of Sample Analyzed

§  Saliva Samples

§  Other Samples

§  Type of Sample Collection Method

§  At-home Sample Collection

§  Lab Sample Collection

§  Key Geographical Regions 

§  North America

§  Europe

§  Asia-Pacific

§  Latin America

§  MENA

§  Rest of the World 

The report features inputs from eminent industry stakeholders, according to whom, continuous growth of nutrigenomics market is primarily driven by the increasing adoption for personalized heathcare. The report includes detailed transcripts of discussions held with the following experts:

§  Kate Scott (Co-Founder, DNApal.me)

§    Vishwajeet Jathar (Co-founder, Genescope.ai HealthTech)

§  Simon Bradley (Founder, Percent-Edge)

§  Mehdi Maghsoodnia (Chief Executive Officer, Vitagene / 1Health)

The research also includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its nutrigenomics focused service portfolio, recent developments and an informed future outlook.

§  3X4 Genetics

§  Advanced Nutrigenomics

§  DNAlysis Biotechnology

§  DNA Health and Wellness

§  Geno Palate

§  Mapmygenome

§  Nutrigenetix

§  Nutrigenomix

§  Vieroots

§  Vitagenum

For additional details, please visit https://www.rootsanalysis.com/reports/nutrigenomics-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.

Given the ever-increasing demand for tissue transplantation, primarily for wound and bone healing, there is an urgent need for safe and efficient products that enable healing and regeneration. At present, the supply of tissue donations is insufficient to satisfy the required demand. It is worth highlighting that, in recent years, tissue engineering and regenerative medicine have emerged as promising alternatives for tissue regeneration.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/tissue-engineering-market/request-sample.html

Key Market Insights

Over 115 tissue engineering-based skin regeneration products are presently available in this market space

About 50% of the total products are intended for wound healing, followed by developed for the purpose of surgical healing. Further, more than 50% of the products are made of human placental tissues, followed by those developed using other animal-based tissues.

~40 tissue engineering-based bone regeneration products are being offered by developers, globally

About 55% of the total products are made from bone tissues, followed by those developed using stem cells. In fact, most of the products are formulated in the form of a sheet (10), followed by those developed in the form of a bone matrix. Further, nearly 75% of the products are available in the form of xenografts.

Around 60 players are engaged in the development of the tissue engineering-based regeneration products

Majority of the players engaged in this domain are mid-sized firms (51-500 employees, 31%), followed by small players (11-51 employees, 27%), large players (1000-5000 employees, 26%) and very small (2-10 employees, 10%) companies. It is worth noting that ~40% developers are based in North America.

Till date, 750+ grants have been awarded for tissue engineering-based regeneration products

For research and development activity of tissue engineering-based regeneration products, grant amount of close to USD 300 million has been awarded in last five years. Further, 70% of this amount was awarded in 2021 alone.

Patent activity in this domain has grown at a CAGR of ~11%, between 2012 and 2022

R&D activity related to tissue engineering-based regeneration products is largely concentrated in North America; this can be validated from the fact that about 40% of the total patents were filed in this region, followed by the World Intellectual Property Organization (30%) and Asia-Pacific region (20%).

More than USD 2 billion Invested by industry and non-industry stakeholders in the last five years

Majority of the companies primarily received funding through private placements (~25%) and debt financing (~20%) rounds. It is worth mentioning that, over 95% of the amount was invested in companies based in North America.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2022

Large companies have inked the highest number of partnerships related to tissue engineering-based regeneration products, In addition nearly 40% majority of the agreements reported in tissue engineering market were instances of mergers and acquisitions.

North America is expected to capture more than 55% share in the tissue engineering-based regeneration products market by 2035

In terms of area of application, the current market is anticipated to be driven by products intended for skin healing (~50%), followed by those targeting bone healing (~30%). Further, xenograft-based products are expected to grow at a relatively faster pace (10.58%), till 2035.

Key Questions Answered

§  Who are the leading players engaged in providing tissue engineering-based regeneration products?

§  Which tissue engineering-based regeneration product is most commonly offered by developers?

§  What is the relative competitiveness of tissue engineering-based regeneration product providers?

§  What types of partnership models are commonly being adopted by stakeholders in this industry?

§  What is the trend for capital investments in the tissue engineering-based regeneration products market?

§  How has the patent landscape in this domain evolved over the last two decades?

§  What is the overall trend of grant activity related to tissue engineering-based regeneration products?

§  Which key market trends and driving factors are likely to impact the growth of the tissue engineering-based regeneration products market?

§  How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:

§  Type of Graft

§  Allografts

§  Autografts

§  Xenografts

§  Area of Application

§  Bone Healing

§  Burn Healing

§  Wound Healing

§  Surgical Healing

§  Others

§  Key Geographical Regions

§  Ambulatory Surgical Centers

§  Hospitals

§  Specialty Clinics

§  Key Geographical Regions

§  North America

§  Europe

§  Asia

§  Middle East and North Africa

§  Latin America

§  Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.

§  AlloSource

§  Bio-Tissue

§  Integra LifeSciences

§  MiMedx

§  Organogenesis

§  Smith+Nephew

§  Tissue Regenix

§  VIVEX Biologics

For additional details, please visit https://www.rootsanalysis.com/reports/tissue-engineering-market.html

You may also be interested in the following titles:

1.      Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035

2.      Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

London

Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.

With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. With the growing need for therapies targeting AMR infections, bacteriophage therapy is now gaining more traction.

Key Market Insights

Close to 15 bacteriophage therapeutics are commercialized, while more than 90 are currently at different stages of development 

Close to 50% of the pipeline candidates are under clinical evaluation; majority (91%) of these candidates are being developed for the treatment of infectious diseases, targeting wide range of bacterial strains.

40+ industry stakeholders claim to have the required capability to manufacture bacteriophage therapeutics

The bacteriophage therapy market is currently dominated by the presence of various small players (48%); of these 55% of the players are located in North America, followed by Europe (35%).

More than 2,200 articles focused on bacteriophage therapeutics have been published, since 2018

Around 40% of these were published in the last two years, indicating the extensive research activity being carried out in this domain.

Close to USD 1,200 million has been invested by both private and public investors, since 2017

Of the total amount invested, over USD 330 million was raised through venture capital funding, representing close to 30% of the overall funding activity in this domain. Further, close to 40% of the instances were, wherein players were collectively awarded more than USD 300 million.

Partnership activity within this domain has grown significantly between the time period, 2017-2021

Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that, majority of the deals were related to the research and development (20%), followed by agreements signed for product development (15%).

More than 3,500 patients have been enrolled in over 40 clinical trials, worldwide

Clinical research activity, in terms of number of trials registered, is reported to has significantly increased in the past few years. Of the total number of trials, close to 35% have already been completed, while 41% are active and still recruiting patients.

Europe are anticipated to capture larger share (~95%) of the market by 2035

Currently, in bacteriophage therapeutics market, gastrointestinal infections capture the highest share (~50%) and this trend is unlikely to change in the foreseen future. Further, more than 55% share of the market is captured by oral bacteriophage therapeutics.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market/request-sample.html

Key Questions Answered

§  Which bacteriophage therapeutics candidates are currently under clinical stage of development pipeline?

§  Who are the leading players engaged in the development of bacteriophage therapeutics?

§  Which geographies are the most active in conducting clinical trials related to bacteriophage therapeutics?

§  What is the focus of various publications related to bacteriophage therapeutics?

§  Which partnership models are commonly adopted by industry and non-industry stakeholders?

§  What are the investment trends in the industry?

§  What are the different initiatives undertaken by start-ups for the development of bacteriophage therapeutics in the recent past?

§  How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:

§  Type of Therapeutic Area

§  Gastrointestinal Infections

§  Bacterial Dysentery

§  Multiple Infections

§  Other Infections

§  Distribution by Route of Administration

§  Oral Route

§  Rectal Route

§  Intravesical Route

§  Topical Route

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

§  Latin America

§  Middle East and North Africa

The report features inputs from eminent industry stakeholders, according to whom upcoming generations of bacteriophage therapeutics are likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:

§  Antoine Culot (Chief Executive Officer, Rime Bioinformatics)

§  Mathieu Medina (Project Leader, Hospices Civils De Lyon)

§  Iddo Weiner (Senior Director, Head of Data-Science, BiomX)

§  Mohammadreza Azizkhani (Independent Consultant)

The research also includes detailed profiles of key players (listed below), featuring an overview of the company, its financial information (if available), detailed information on the advanced stage pipeline candidates and an informed future outlook.

§  Adaptive Phage Therapeutics

§  ContaFect

§  Eliava BioPreparations

§  Micreos

§  NPO Microgen

§  Phagelux

§  Pherecydes Pharma

For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Some benefits of using smart labels in the healthcare sector are briefly described below.

§  Clinical Trial Labelling: The tracking of medication consumption during clinical phase testing processes can be improved using the smart label technology. This can also enable the Food and Drug Administration (FDA) of the United States to enhance the efficiency of the drug approval process and decrease the time required for the same, by improving tracking and accountability.

§  Inventory Management: In order to gain an accurate insight on inventory, manufacturers required enhances visibility throughout the supply chain. Lack of such visibility can often lead to multiple challenges, including increased inventory. On the other hand, use of smart labels can mitigate this challenge, eventually enabling reduction in overall costs.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/smart-labels-market/request-sample.html

Medical Device and Asset Tracking: RFID offers a wide range of possible applications for the medical device industry. Medical device manufacturers are required by the FDA to be able to identify each item by a unique serial number, as device recalls might happen more than 50% of the time. Therefore, medical device producers need to exercise more control.

§  over implants that are on consignment with the hospitals. Faster redeployment would be possible with RFID technology that enhances visibility into returns, as the business is more aware of when an unused product might be returned.

§  Patient Tracking: In case of medical emergencies, when immediate treatment is required, smart label equipped patient badges can help in patient identification in order to ensure safety of patients.

§  Product Tracking: Currently, hospitals and industry stakeholders are required to keep track of radioactive isotopes wherever they are located, from storage to transit to administration to disposal. These processes may be automated with RFID tags and scanners, saving time and resources. Seal integrity for containers and individual items may be checked with active RFID tags that have read / write capability. Even issues that arise in the middle of a shipment can be identified due to the tag's ability to record the timing and length of seal loss.

§  Supply Chain Tracking:  Smart label tracking across the supply chain provides businesses with the knowledge of the whole sourcing and product path and aids in preventing grey market diversion, selling of goods by unauthorized reseller.

Based on type of technology our estimates suggest that the overall market is likely to be driven by revenues generated through RFID; this can be attributed to the fact that RFID represents the highest percentage of the total smart labels market in 2022. According to our projections, presently, the smart pharmaceutical and healthcare labels market markets in North America and Europe are likely to capture the highest (67%) share.

For additional details, please visit https://www.rootsanalysis.com/reports/smart-labels-market.html

You may also be interested in the following titles:

1.      Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035

2.      Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

It is worth highlighting that 50% players developing 4D bioprinters have established their presence in the domain after 2012. This indicates that the market is driven by the efforts of new players, majority of which have around 10 years of experience; prominent examples include (in reverse chronological order of their year of establishment) BRIGHTER (2020), Readily3D (2020), TissueLabs (2019) and Nuclera (2013). It is worth mentioning that pre-1985, seven companies have been established; examples include (in reverse chronological order of their year of establishment) 3D Systems (1983), University of Wollongong (1975) and Rutgers University (1766). Presently, the 4D bioprinting technology is being explored for use across various application areas in the biomedical industry, leading to an increase in opportunities within this domain

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/4d-bioprinting-market/request-sample.html

Further, 55% players developing smart biomaterials have entered this field before 1970. This indicates that the market is driven by the efforts of well-established players, majority of which have more than 45 years of experience; prominent examples include (in reverse chronological order of their year of establishment) University of Birmingham (1900), RWTH Aachen University (1870), University of Georgis (1785) and Harvard University (1636). It is worth mentioning that post 2014, six new companies have been established; examples include (in reverse chronological order of their year of establishment) Instituto de Nanociencia y Materiales de Aragón (2020), 4D Biomaterials (2018), NanoBio Lab (2018), 1ST GRAPHENE (2016), NanoRegMed (2016) and Grolltex (2015)

Moreover, companies developing 4D bioprinters and smart biomaterials have been segregated under three categories, namely small (less than 50 employees), mid-sized (51-500 employees) and large companies (more than 500 employees). It is important to mention that, for the purpose of this analysis, information has been sourced primarily from company websites and other reliable sources, such as LinkedIn.

As can be observed in the figure, polymer (58%) emerged as the most preferred type of biomaterial. This is followed by natural type of biomaterial (49%). It is worth mentioning that biomaterials offer variety of applications such as making implants / protheses and medical devices, as they have the unique ability to replace or restore the lost or impaired bodily functions.

Further, 58% 4D bioprinters have already been commercialized while 42% 4D bioprinters are under development phase. Examples of some commercialized 4D bioprinters include (in alphabetical order, no selection criteria) NGB-R, Organ.Aut, Origin One and Tomolite.

Moreover, laser-based technology is the most preferred (42%) type of technology used in 4D bioprinters. This can be attributed to the fact that lased-based technology utilizes a nozzle free approach. The presence of nozzle can harm the cell viability sometimes, while its absence significantly improves the same. Further, this nozzle-free approach also allows to adjust the viscosity of bioink as per the need.

As can be observed in the figure, 23% polymer-based smart biomaterials and 8% smart biomaterials made of natural components have already been commercialized. While 44% polymer-based smart biomaterials and 20% smart biomaterials made of natural components are under development. Notable examples of commercialized polymer-based smart biomaterials include (in alphabetical order, no selection criteria) 4Degra resin ink, SLA Resins and Porcine collagen-based hydrogel.

Further, maximum number of smart biomaterials (23%) are available in sheet form. This is followed by 14% smart biomaterials available in liquid form. Further, there are 11% smart biomaterials available in gel and versatile forms, each.

Moreover, most of the smart biomaterials (28) marketed / being developed can be used in the field of tissue engineering and regenerative medicine. It is worth mentioning that 4D printed pictures of tissues are used to manufacture patient-specific tissue structures using computer-aided design (CAD), along with other digital imaging methods such as magnetic resonance imaging (MRI) and X-ray computed tomography (CT). This is followed by six smart biomaterials that can be applied in the domain of orthopedics.

For additional details, please visit https://www.rootsanalysis.com/reports/4d-bioprinting-market.html

You may also be interested in the following titles:

1.      Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035

2.      Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

It is worth highlighting that 50% players developing 4D bioprinters have established their presence in the domain after 2012. This indicates that the market is driven by the efforts of new players, majority of which have around 10 years of experience; prominent examples include (in reverse chronological order of their year of establishment) BRIGHTER (2020), Readily3D (2020), TissueLabs (2019) and Nuclera (2013). It is worth mentioning that pre-1985, seven companies have been established; examples include (in reverse chronological order of their year of establishment) 3D Systems (1983), University of Wollongong (1975) and Rutgers University (1766). Presently, the 4D bioprinting technology is being explored for use across various application areas in the biomedical industry, leading to an increase in opportunities within this domain

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/4d-bioprinting-market/request-sample.html

Further, 55% players developing smart biomaterials have entered this field before 1970. This indicates that the market is driven by the efforts of well-established players, majority of which have more than 45 years of experience; prominent examples include (in reverse chronological order of their year of establishment) University of Birmingham (1900), RWTH Aachen University (1870), University of Georgis (1785) and Harvard University (1636). It is worth mentioning that post 2014, six new companies have been established; examples include (in reverse chronological order of their year of establishment) Instituto de Nanociencia y Materiales de Aragón (2020), 4D Biomaterials (2018), NanoBio Lab (2018), 1ST GRAPHENE (2016), NanoRegMed (2016) and Grolltex (2015)

Moreover, companies developing 4D bioprinters and smart biomaterials have been segregated under three categories, namely small (less than 50 employees), mid-sized (51-500 employees) and large companies (more than 500 employees). It is important to mention that, for the purpose of this analysis, information has been sourced primarily from company websites and other reliable sources, such as LinkedIn.

As can be observed in the figure, polymer (58%) emerged as the most preferred type of biomaterial. This is followed by natural type of biomaterial (49%). It is worth mentioning that biomaterials offer variety of applications such as making implants / protheses and medical devices, as they have the unique ability to replace or restore the lost or impaired bodily functions.

Further, 58% 4D bioprinters have already been commercialized while 42% 4D bioprinters are under development phase. Examples of some commercialized 4D bioprinters include (in alphabetical order, no selection criteria) NGB-R, Organ.Aut, Origin One and Tomolite.

Moreover, laser-based technology is the most preferred (42%) type of technology used in 4D bioprinters. This can be attributed to the fact that lased-based technology utilizes a nozzle free approach. The presence of nozzle can harm the cell viability sometimes, while its absence significantly improves the same. Further, this nozzle-free approach also allows to adjust the viscosity of bioink as per the need.

As can be observed in the figure, 23% polymer-based smart biomaterials and 8% smart biomaterials made of natural components have already been commercialized. While 44% polymer-based smart biomaterials and 20% smart biomaterials made of natural components are under development. Notable examples of commercialized polymer-based smart biomaterials include (in alphabetical order, no selection criteria) 4Degra resin ink, SLA Resins and Porcine collagen-based hydrogel.

Further, maximum number of smart biomaterials (23%) are available in sheet form. This is followed by 14% smart biomaterials available in liquid form. Further, there are 11% smart biomaterials available in gel and versatile forms, each.

Moreover, most of the smart biomaterials (28) marketed / being developed can be used in the field of tissue engineering and regenerative medicine. It is worth mentioning that 4D printed pictures of tissues are used to manufacture patient-specific tissue structures using computer-aided design (CAD), along with other digital imaging methods such as magnetic resonance imaging (MRI) and X-ray computed tomography (CT). This is followed by six smart biomaterials that can be applied in the domain of orthopedics.

For additional details, please visit https://www.rootsanalysis.com/reports/4d-bioprinting-market.html

You may also be interested in the following titles:

1.      Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035

2.      Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

It is worth highlighting that 50% players developing 4D bioprinters have established their presence in the domain after 2012. This indicates that the market is driven by the efforts of new players, majority of which have around 10 years of experience; prominent examples include (in reverse chronological order of their year of establishment) BRIGHTER (2020), Readily3D (2020), TissueLabs (2019) and Nuclera (2013). It is worth mentioning that pre-1985, seven companies have been established; examples include (in reverse chronological order of their year of establishment) 3D Systems (1983), University of Wollongong (1975) and Rutgers University (1766). Presently, the 4D bioprinting technology is being explored for use across various application areas in the biomedical industry, leading to an increase in opportunities within this domain

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/4d-bioprinting-market/request-sample.html

Further, 55% players developing smart biomaterials have entered this field before 1970. This indicates that the market is driven by the efforts of well-established players, majority of which have more than 45 years of experience; prominent examples include (in reverse chronological order of their year of establishment) University of Birmingham (1900), RWTH Aachen University (1870), University of Georgis (1785) and Harvard University (1636). It is worth mentioning that post 2014, six new companies have been established; examples include (in reverse chronological order of their year of establishment) Instituto de Nanociencia y Materiales de Aragón (2020), 4D Biomaterials (2018), NanoBio Lab (2018), 1ST GRAPHENE (2016), NanoRegMed (2016) and Grolltex (2015)

Moreover, companies developing 4D bioprinters and smart biomaterials have been segregated under three categories, namely small (less than 50 employees), mid-sized (51-500 employees) and large companies (more than 500 employees). It is important to mention that, for the purpose of this analysis, information has been sourced primarily from company websites and other reliable sources, such as LinkedIn.

As can be observed in the figure, polymer (58%) emerged as the most preferred type of biomaterial. This is followed by natural type of biomaterial (49%). It is worth mentioning that biomaterials offer variety of applications such as making implants / protheses and medical devices, as they have the unique ability to replace or restore the lost or impaired bodily functions.

Further, 58% 4D bioprinters have already been commercialized while 42% 4D bioprinters are under development phase. Examples of some commercialized 4D bioprinters include (in alphabetical order, no selection criteria) NGB-R, Organ.Aut, Origin One and Tomolite.

Moreover, laser-based technology is the most preferred (42%) type of technology used in 4D bioprinters. This can be attributed to the fact that lased-based technology utilizes a nozzle free approach. The presence of nozzle can harm the cell viability sometimes, while its absence significantly improves the same. Further, this nozzle-free approach also allows to adjust the viscosity of bioink as per the need.

As can be observed in the figure, 23% polymer-based smart biomaterials and 8% smart biomaterials made of natural components have already been commercialized. While 44% polymer-based smart biomaterials and 20% smart biomaterials made of natural components are under development. Notable examples of commercialized polymer-based smart biomaterials include (in alphabetical order, no selection criteria) 4Degra resin ink, SLA Resins and Porcine collagen-based hydrogel.

Further, maximum number of smart biomaterials (23%) are available in sheet form. This is followed by 14% smart biomaterials available in liquid form. Further, there are 11% smart biomaterials available in gel and versatile forms, each.

Moreover, most of the smart biomaterials (28) marketed / being developed can be used in the field of tissue engineering and regenerative medicine. It is worth mentioning that 4D printed pictures of tissues are used to manufacture patient-specific tissue structures using computer-aided design (CAD), along with other digital imaging methods such as magnetic resonance imaging (MRI) and X-ray computed tomography (CT). This is followed by six smart biomaterials that can be applied in the domain of orthopedics.

For additional details, please visit https://www.rootsanalysis.com/reports/4d-bioprinting-market.html

You may also be interested in the following titles:

1.      Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035

2.      Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

It is worth highlighting that 50% players developing 4D bioprinters have established their presence in the domain after 2012. This indicates that the market is driven by the efforts of new players, majority of which have around 10 years of experience; prominent examples include (in reverse chronological order of their year of establishment) BRIGHTER (2020), Readily3D (2020), TissueLabs (2019) and Nuclera (2013). It is worth mentioning that pre-1985, seven companies have been established; examples include (in reverse chronological order of their year of establishment) 3D Systems (1983), University of Wollongong (1975) and Rutgers University (1766). Presently, the 4D bioprinting technology is being explored for use across various application areas in the biomedical industry, leading to an increase in opportunities within this domain

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/4d-bioprinting-market/request-sample.html

Further, 55% players developing smart biomaterials have entered this field before 1970. This indicates that the market is driven by the efforts of well-established players, majority of which have more than 45 years of experience; prominent examples include (in reverse chronological order of their year of establishment) University of Birmingham (1900), RWTH Aachen University (1870), University of Georgis (1785) and Harvard University (1636). It is worth mentioning that post 2014, six new companies have been established; examples include (in reverse chronological order of their year of establishment) Instituto de Nanociencia y Materiales de Aragón (2020), 4D Biomaterials (2018), NanoBio Lab (2018), 1ST GRAPHENE (2016), NanoRegMed (2016) and Grolltex (2015)

Moreover, companies developing 4D bioprinters and smart biomaterials have been segregated under three categories, namely small (less than 50 employees), mid-sized (51-500 employees) and large companies (more than 500 employees). It is important to mention that, for the purpose of this analysis, information has been sourced primarily from company websites and other reliable sources, such as LinkedIn.

As can be observed in the figure, polymer (58%) emerged as the most preferred type of biomaterial. This is followed by natural type of biomaterial (49%). It is worth mentioning that biomaterials offer variety of applications such as making implants / protheses and medical devices, as they have the unique ability to replace or restore the lost or impaired bodily functions.

Further, 58% 4D bioprinters have already been commercialized while 42% 4D bioprinters are under development phase. Examples of some commercialized 4D bioprinters include (in alphabetical order, no selection criteria) NGB-R, Organ.Aut, Origin One and Tomolite.

Moreover, laser-based technology is the most preferred (42%) type of technology used in 4D bioprinters. This can be attributed to the fact that lased-based technology utilizes a nozzle free approach. The presence of nozzle can harm the cell viability sometimes, while its absence significantly improves the same. Further, this nozzle-free approach also allows to adjust the viscosity of bioink as per the need.

As can be observed in the figure, 23% polymer-based smart biomaterials and 8% smart biomaterials made of natural components have already been commercialized. While 44% polymer-based smart biomaterials and 20% smart biomaterials made of natural components are under development. Notable examples of commercialized polymer-based smart biomaterials include (in alphabetical order, no selection criteria) 4Degra resin ink, SLA Resins and Porcine collagen-based hydrogel.

Further, maximum number of smart biomaterials (23%) are available in sheet form. This is followed by 14% smart biomaterials available in liquid form. Further, there are 11% smart biomaterials available in gel and versatile forms, each.

Moreover, most of the smart biomaterials (28) marketed / being developed can be used in the field of tissue engineering and regenerative medicine. It is worth mentioning that 4D printed pictures of tissues are used to manufacture patient-specific tissue structures using computer-aided design (CAD), along with other digital imaging methods such as magnetic resonance imaging (MRI) and X-ray computed tomography (CT). This is followed by six smart biomaterials that can be applied in the domain of orthopedics.

For additional details, please visit https://www.rootsanalysis.com/reports/4d-bioprinting-market.html

You may also be interested in the following titles:

1.      Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035

2.      Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Currently, various AI algorithms are being used in cancer imaging. Roots Analysis is pleased to announce the publication of its recent study, titled, “Artificial Intelligence in Oncology Market, 2022-2035.” It is worth highlighting that 26% of the players engaged in this domain are using both machine learning and deep learning technologies.

To request a sample copy / brochure of this report, please visit this

https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this technology over the next decade.  It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed overview of the overall market landscape of players engaged in the development of artificial intelligence in oncology software solutions. 

§  Elaborate profiles of prominent players that specialize in offering artificial intelligence in oncology- based software solutions.

§  A competitiveness analysis of artificial intelligence in oncology- based software providers, based on supplier strength, portfolio diversity and portfolio strength.

§  An in-depth analysis of patents related to artificial intelligence in oncology- based software solutions, filed / granted till date.

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  A detailed analysis of various investments made by players engaged in this domain, during the period 2017-2021.

§  A detailed analysis of the current and future market based on blue ocean strategy, covering a strategic plan / guide for emerging players in this domain to help unlock an uncontested market.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

• Type of Cancer

§  Solid Malignancies

§  Breast Cancer

§  Lung Cancer

§  Prostate Cancer

§  Colorectal Cancer

§  Brain Tumor

§  Others

• Type of End-User

§  Hospitals

§  Pharma Companies

§  Research Institutes

§  Others

• Key Geographical Regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the World

Key companies covered in the report

§  Ibex Medical Analytics

§  Niramai

§  Optellum

§  Tempus Labs

§  Paige

§  Kheiron Medical Technologies

For additional details, please visit https://www.rootsanalysis.com/reports/ai-in-oncology-market.html

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “Monkeypox Market: Focus on Therapeutics, Vaccines and Diagnostic Kits, 2023-2035” report to its list of offerings.

Given the increase in research and development activity in this domain and the substantial financial assistance provided by public funding institutes, the monkeypox therapeutics / vaccines and diagnostic kits market is projected to grow at a steady pace in the near future. The recent rise in the incidence of the monkeypox disease, also known as Mpox, has compelled both industry players and regional government authorities to undertake active initiatives in order to control the spread of the disease

Key Market Insights

25+ monkeypox therapeutics and vaccines are currently approved / under development

More than 20% of the aforementioned candidates are approved or have been granted expanded access for the treatment / prevention of monkeypox. Further, 70% of the total candidates are in preclinical stages of development. It is also worth noting that ~65% of the candidates in development pipeline are biologics.

Over 120 developers claim to provide diagnostic kits for monkeypox virus detection

Interestingly, nearly 65% of the diagnostic kit providers are based in Asia-Pacific and rest of the world. Notably, around 50% of the total players engaged in this space are mid-sized firms. Additionally, over 75% of monkeypox diagnostic kits use polymerase chain reaction (PCR) as a detection method.

Partnership activity within this domain has grown at a CAGR of ~150%, between 2018 and 2022

More than 85% of the partnerships were inked in the year 2022, indicating the recent surge in interest of industry stakeholders in this domain. Further, majority of the deals were supply agreements (75%), and primarily focused on expanding their global reach.

More than 250 grants have been awarded for research related to monkeypox therapeutics, vaccines and diagnostic solutions

Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, microbiology / immunology / virology departments emerged as the key research departments, having received over 35% of the total grants.

Over 230 articles related to monkeypox therapeutics, vaccines and diagnostic kits have been published between 2018 and 2022

35% of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that close to 90% of the total articles were published post-2020, highlighting the growing research activity in the recent years.

North America and Europe are anticipated to capture close to 95% share of the monkeypox therapeutics and vaccines market, by 2035

The monkeypox therapeutics / vaccines market’s evolution is likely to be driven by the rising need for novel drug candidates. In terms of type of product, vaccines are expected to occupy a larger share (99%) of the overall monkeypox therapeutics and vaccines market in 2035.

PCR Kits are anticipated to capture more than 70% share of the monkeypox diagnostic kits market, by 2035

In the long term, hospitals and clinics are likely to contribute to a majority share (~50%) of revenues as end users. Further, North America and Europe are anticipated to capture close to 70% share of the monkeypox diagnostic kits market.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/monkeypox-treatment-market/request-sample.html

Key Questions Answered

§  What are the factors driving the overall monkeypox market?

§  Who are the key players engaged in the development of monkeypox therapeutics / vaccines, and diagnostic kits?

§  How many therapeutics and vaccines are approved for the treatment and prevention of monkeypox?

§  What is the count of monkeypox diagnostic kits that are currently available in the market?

§  What are the partnership and collaboration trends observed in relation to monkeypox therapeutics / vaccines and diagnostic kits?

§  Which segment, in terms of type of product, accounts for the largest monkeypox therapeutics / vaccines market share?

§  Which type of diagnostic kit accounts for the largest monkeypox market share?

The financial opportunity within the within the monkeypox therapeutics / vaccines and diagnostic kits market has been analyzed across the following segments:

§  Type of Product

§  Therapeutics

§  Vaccines

§  Developer

§  Bavarian Nordic

§  Emergent BioSolutions

§  KM Biologics

§  SIGA Technologies

§  Type of Kit

§  Polymerase Chain Reaction (PCR) Detection Kits

§  Antigen Detection Kits

§  Antibody Detection Kits

§  Type of End User

§  Hospitals and Clinics

§  Diagnostic Laboratories

§  Other End Users

§  Key Geographical Regions

§  North America (US and Canada)

§  Europe (UK, France, Germany, Spain, Italy, Rest of EU)

§  Asia-Pacific (Japan and Australia)

§  Rest of the World

The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. According to industry experts the monkeypox therapeutics / vaccines and diagnostic kits market is likely to grow over the coming years if the disease becomes a pandemic. The report features detailed transcripts of interviews held with the following industry stakeholders:

§  Willy Tozoke Laou Man Cheong (Business Director, Hunan Runmei Gene Technology)

§  John W Sharkey (Vice President, Business Development, GeoVax)

§  Horace Lee (Sales Manager, Firegene)

§  Alan Yu (Sales Manager, Hangzhou Testsea Biotechnology)

The research also includes detailed profiles of key players (listed below) engaged in the monkeypox therapeutics / vaccines and diagnostic kits markets; each profile features a brief overview of the company, details related to its product portfolio (therapeutics / vaccines or diagnostic kits), recent developments and an informed future outlook.

§  Bavarian Nordic

§  Emergent BioSolutions

§  ACON Laboratories

§  altona Diagnostics

§  DNA Software

§  Elabscience

§  Goldsite Diagnostics

§  Hangzhou Testsea Biotechnology

§  Jiangsu Bioperfectus Technologies

§  Lansion Biotechnology

For additional details, please visit 

https://www.rootsanalysis.com/reports/monkeypox-treatment-market.html

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “Bioavailability Enhancement Technologies and Services Market (2^nd Edition), 2022-2035” report to its list of offerings

Considering the existing drug solubility and biocompatibility-related concerns and their impact on drug safety and patient compliance, the demand for bioavailability enhancement solutions has gained significant traction from the medical community. Drug developers have demonstrated a preference to continue relying on bioavailability enhancement service and technology providers, in order to optimize drug development cost and research timelines. Furthermore, driven by the large number of BCS class II and IV therapies in the current pipeline and growing demand for effective therapeutics, the bioavailability enhancement services market is expected to grow at a steady pace in the foreseen future.

Key Market Insights

~115 players currently claim to be engaged in providing bioavailability enhancement services

The bioavailability enhancement services market landscape is primarily characterized by the presence of small, mid-sized and large firms, which collectively constitute over 75% of the total share. Further, 45% of the service providers are based in North America, followed those having headquarters in Europe and Asia.

More than 75 bioavailability enhancement technologies are presently available in the market

Most (55%) of these technologies support solubility enhancement, followed by those providing support for sustained release drug delivery (46%). Additionally, nearly 70% of the technologies provide bioavailability enhancement services for solids, followed by liquids and fine particles / powders.

Partnership activity in this field has increased at a CAGR of nearly 35%, between 2013 and 2022

Mergers and acquisitions (~40%) emerged as the most common type of partnership models adopted by stakeholders engaged in this industry. Nearly 55% of the total deals were established post-2018, with the maximum activity being reported in 2021.

>9,600 patents related to bioavailability enhancement have been filed / granted, during 2003-2022

Majority (~80%) of the patents were filed as applications, followed by granted patents (20%). It is important to highlight that, nearly 1,200 patents were filed / granted in the year 2021. Further, 36% of the total patents were filed in North America, indicating the extensive R&D activity in this region.

4,700+ clinical trials evaluating bioavailability of drug candidates have been registered worldwide

Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 24%, during the period 2010-2022. Of the total, more than 85% of the studies have already been completed, followed by active trials that are actively recruiting patients (~10%).

Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by stakeholders

The framework highlights the implementation of several advanced as well as traditional bioavailability enhancement approaches and technologies at different stages of the drug development pathway. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating such technologies, based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders.

Shifting focus of drug developers towards development of lipophilic drug compounds is anticipated to drive the demand for bioavailability enhancement technologies and services in the next 13 years

The outsourced commercial demand for bioavailability enhancement is projected to increase at a CAGR of ~10 %. Further, the current clinical demand for solid dosage form captures around 30% of the total demand.

North America and Europe are anticipated to capture more than 65% of the market share, by 2035

Owing to the high prevalence of diseases, increasing investments in formulation development research, and growing initiatives for drug discovery and personalized medicine in Asia, the bioavailability enhancement services market in Asia is likely to grow at a relatively faster pace (13.54%) in the long term. Further, in 2035, bioavailability enhancement services for new chemical entities are expected to dominate the market, capturing around 85% of the market share.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/198/request-sample.html

Key Questions Answered

§  Who are the key players engaged in the bioavailability enhancement technologies and services market?

§  Which are the key geographies where bioavailability enhancement technology and service providers are located?

§  What are the recent developments and expected trends in the bioavailability enhancement industry?

§  Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?

§  What is the evolving trend of publications focused on bioavailability enhancement technologies?

§  Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?

§  What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement services market?

§  How is the current and future opportunity likely to be distributed across key market segment?

The financial opportunity within the bioavailability enhancement services market has been analyzed across the following segments:

§  Drug Class

§  New Drug Approvals

§  Generics

§  BCS Classification

§  BCS II Drugs

§  BCS IV Drugs

§  Bioavailability Enhancement Approach

§  Solid Dispersion

§  Size Reduction

§  Lipid-based

§  Dosage Form

§  Liquids

§  Solids

§  Semi-Solids

§  Fine Particles / Powders

§  Key Geographies 

§  North America

§  Europe

§  Asia

§  Latin America

§  Middle East and North Africa (MENA)

§  Rest of the World 

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), recent developments (including partnerships and collaborations) and an informed future outlook.

§  Adare Pharma Solutions

§  Ascendia Pharmaceuticals

§  Catalent

§  Lonza

§  Lubrizol Life Science Health

§  Pace Life Sciences

§  Quotient Sciences

§  WuXi STA (a subsidiary of WuXi AppTec)

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html   

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Further, we have also highlighted the Cooperative Patent Classification (CPC) symbols and leading players (in terms of number of patents filed / granted). Moreover, the module includes an informed patent benchmarking analysis of the top patent applicants, along with an analysis of the relative valuation of patents filed / granted related to viral clearance testing, based on several parameters, such as patent age, region in which patent is filed / granted and number of citations.

For the purpose of this analysis, information on patents was extracted from a reliable database, lens.org. The database groups patent applications into different patent families and covers intellectual property documents filed with different patent offices, across the globe. Around 65% of the patents filed related to viral clearance and viral testing were applications (not having received approval yet), followed by granted patents. It is worth highlighting that, the maximum number of patents (over 50) related to this domain were filed / granted in 2020. Further, close to 35 patents have been filed / granted in 2022 (till September)

To request a sample copy / brochure of this report, please visit this

https://www.rootsanalysis.com/reports/viral-clearance-and-testing-services-market/request-sample.html

Based on several relevant parameters, such as patent type, patent age, number of citations, and region, the patents were allotted different valuation scores. Our analysis indicates that only 1% of patents have the highest relative valuation, based on the parameters and the cut-off of the weighted score considered for this analysis. This is primarily because of the relatively low citations of the patents that have been filed recently, leading to low patent value.

In terms of Geography, most of the patents (36%) were filed / granted in Asia-Pacific. Within this region, the maximum number of patents (over 40) were filed in China. This is followed by North America, where 32% of the total patents were filed / granted. The number of patents is indicative of the extensive research activity taking place in these regions. more than 85% of the players efficiently analyze antibodies for viral contamination, followed by players that have capability to analyze cell and gene therapies, vaccines and recombinant proteins (59%, each) for viral contamination

For additional details, please visit 

https://www.rootsanalysis.com/reports/viral-clearance-and-testing-services-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Owing to its ability to print complex models using a wide range of materials, 3D printing has applications across various industries, including dental, aerospace, automotive, healthcare, food, fashion, mechanical engineering and other manufacturing industries.

To request a sample copy / brochure of this report, please visit this

https://www.rootsanalysis.com/reports/dental-3d-printing-market/request-sample.html

It is worth mentioning that the number of dental 3D printer manufacturers has gradually increased over the past decades. In recent years, the adoption of 3D printers has risen at a commendable pace, specifically in the dental industry. This is primarily due to the increasing scope of inhouse dental 3D printing, growth in digital dentistry business and rise in the demand for 3D printed products. 3D printing in dental industry is an advanced solution which produces high quality and more accurate dental products (including, crown and bridges, dentures, surgical guides and dental implants). Moreover, the process of dental 3D printing is time saving and economical for both the patients and dentists. Driven by the growing prevalence of dental diseases and rising demand for high quality dental products, the dental 3D printing market is anticipated to witness a steady growth in the foreseen future. During our research, we identified 80 dental 3D printers companies offered close to 230 dental 3D printers across the globe. 

For additional details, please visit 

https://www.rootsanalysis.com/reports/dental-3d-printing-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

It involves various processes such as target identification, validation, hit generation, hit to lead and lead optimization. Whereas development include optimization and formulation, clinical trials and final approval by authorized regulatory. However, despite of the advances in technology drug discovery process is still considered to be complex, expensive and lengthy. In order to address such concerns, drug developers are shifting their focus from traditional techniques to the use of novel discovery techniques. Presently, Quantum Computing has emerged as one of the prominent technologies.  The use of quantum computing has shown to help the drug developers in selecting potential lead candidates, having the desired physiochemical and pharmacokinetic properties, without having to conduct extensive screening procedures. 

To request a sample copy / brochure of this report, please visit this

https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery/request-sample.html

Quantum computing is a process, using law of quantum mechanics to solve large and complex problems in short span as compared to the computer aided drug discovery.  Currently, there are several quantum computing related approaches that are being used in the drug discovery process alone, such as structure-based drug design, fragment-based drug discovery and ligand-based drug discovery. The predictive power of quantum computing has proven to reduce the complexity, cost and time investment in drug discovery procedure by allowing researchers to bypass the random screening of billions of molecules in a short span of time

Advantages of Quantum Computing in Drug Discovery:

§  Faster Computation: It has a potential to perform computation at much higher rate. It is useful in target identification by enabling its deeper exploration of complex therapeutic area

§  Cost Benefits: It has capability to allow cost effective analysis. It reduces the expensive lab testing by enhancing the screening accuracy of the targeted molecules.

§  Facilitate the design of Clinical Trials: Quantum computing accelerate the design of clinical trial which. further helps in building virtual patients for clinical trials. This potentially reduces time of trials and increasing quality.

§  Reduce discovery timeline: It accelerates the high throughput screening of multiple targeted molecules at a given time hence reducing the discovery timeline of drugs.

§  Possible modeling of complex molecules: It helps molecular modelers to achieve new level of accuracy by modeling complex molecule interaction. It focuses on different target area and increases the affinity towards the targeted molecules.

Majority of the quantum computing software providers (45%) engaged in this domain were established post-2016. This is indicative of the growing interest of stakeholders in this domain. Examples of recently established companies include (post-2019, in alphabetical order) Algorithmiq (2020), Kuano (2020), Polaris Quantum Biotech (2020), Qubit Pharmaceuticals (2020) and Qunova Computing (2021). Hence, it can be concluded that players offering quantum computing services in drug discovery have now become an integral part of the pharmaceutical industry. Furthermore, considering the various active initiatives being undertaken by players based in this domain, we are led to believe that the opportunity for stakeholders in this niche, upcoming, industry is likely to grow at an exponential pace in the foreseen future.

For additional details, please visit 

https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

The industry has witnessed the entry of 7% players, since 2015. Of these, over four are based in Asia-Pacific and five in North America. Examples of the recently established players include (established post 2016, in reverse chronological order) Resilience (2020), Liof Pharma (2020), JOINN Biologics (2018), Exelead (2017), Esco Aster (2017) and CMAB Biopharma (2017). Of these, three companies, namely JOINN Biologics, Exelead and Esco Aster have spun-out from their parent companies, which have been operating in the biopharmaceutical domain for several decades.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/256/request-sample.html

Moreover, companies offering biologics fill / finish have been segregated under three categories, namely small (less than 50 employees), mid-sized (51-500 employees) and large companies (more than 500 employees). It is important to mention that, for the purpose of this analysis, information has been sourced primarily from company websites and other reliable sources, such as LinkedIn.

It is evident from the figure that more than 70% of the service providers have capabilities to operate at all scales; majority (over 35%) of such players are based in North America, followed by Europe (around 35%). Examples of such players include (established post 2010, in alphabetical order), AbbVie Contract Manufacturing, Argonaut Manufacturing Services, Alcami, Berkshire Sterile Manufacturing, Exelead, JOINN Biologics, Novex Innovations, PCI Pharma Services, Pfizer CentreOne, Tanvex BioPharma and Resilience.

Further, 95% of the services providers employ vials for packaging of biologic drug products. This is followed by players that use syringes (over 65%) for filling biologics. It is worth highlighting that player, such as (in alphabetical order) Argonaut Manufacturing Services, Lonza, Pfizer CentreOne, Recipharm, Siegfried Holding and Sharp employ all type of packaging containers to offer the biologics fill / finish services.

Moreover, around 70% service providers claim to have the required capabilities to process proteins / peptides. This is followed by players that offer fill / finish services for antibodies (67%) and vaccines (63%). Further, vials emerged as the most popular type of container, being employed by 164 service providers for the packaging various type of biologics.

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/biologics-fill-finish-services-market/256.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Given the potential of digital twins to replicate the physical world in a digital layout, as well as their ability to provide real-time outputs, while gathering constant inputs from the real-world, such products have generated significant interest within the healthcare domain

Roots Analysis has announced the addition of “Digital Twins Market, 2022-2035” report to its list of offerings.

Since the first application of the digital twin concept for manufacturing in 2002, it has emerged as a crucial component for companies to achieve higher efficiency in their production processes. According to the US-based Digital Twin Consortium, digital twins hold the potential to reduce clinical trial expenditure, turnaround times, staffing expenses and plan medical intervention. Digital twin technology companies are currently engaged in the development of products which are intended for numerous applications, such as asset / process management, personalized treatment and surgical planning.

Key Market Insights

Over 35 digital twins are presently available in this market space

More than 60% of the digital twins offered by industry players are body part twins; these products are primarily intended for asset / process management, personalized treatment and surgical planning. Further, majority of the products that are currently under development are focused on the treatment of indications, such as cardiovascular disorders, metabolic disorders, and neurological disorders.

More than 30 players currently claim to be engaged in the digital twin domain

Majority of the players engaged in this industry are small firms (11-50 employees, 37%), followed by very large players (10,000+ employees, 22%), large players (501-10,000 employees, 19%), mid-sized players (51-500 employees, 13%) and very small companies (2-10 employees, 9%). Additionally, nearly 70% of the developers are based in Europe, followed by those based in North America (28%).

Partnership activity for digital twins witnessed a CAGR of over 15%, in the past three years

More than 50% of the partnerships have been signed since January 2020; of these, four partnerships were inked in the year 2022. Technology integration agreements have emerged as the most popular (30%) type of partnership model in the market, followed by technology utilization agreements (23%).

Nearly USD 6 billion invested across the globe to advance digital twins focused initiatives

A steady increase has been observed in funding activity since 2020, with the maximum number of instances (10) being reported in the year 2021. In fact, more than 90% of the total investment (in terms of the amount invested) was made in the last two years alone (2021- 2022). Of the amount raised in 2022, about USD 4.2 billion was contributed by the IPO of Babylon.

Berkus start-up valuation analysis has been performed to evaluate start-ups in this domain

The framework enables valuation of start-ups, based on several key success / risk factors  . The key factors are assigned monetary values based on the qualities / risks possessed by a particular player. At the end, all valuations were added to calculate the final valuation of the company.

Players based in North America are anticipated to capture nearly 30% of the market share by 2035

The overall digital twin market is expected to be primarily driven by the growing interest towards automation and prognostic systems. The estimates in our report suggest that digital twins intended to treat cardiovascular disorders are expected to hold 32% share of the market in 2035. It is interesting to mention that market for digital twins intended to serve pharmaceutical companies and medical device manufacturers, collectively, hold over 60% of the market share in 2035.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/digital-twins-market/request-sample.html

Key Questions Answered

§  Who are the leading players engaged in the development of digital twins for the healthcare domain?

§  Which type of digital twin is most commonly offered by developers engaged in this market space?

§  What is the relative competitiveness of different players engaged in the digital twins domain?

§  What is the likely valuation of start-ups involved in the development of digital twins for the healthcare sector?

§  What is the present and likely future demand for digital twins in the overall healthcare sector?

§  What are the anticipated future trends related to digital twins in the healthcare domain?

§  How is the current and future opportunity likely to be distributed across key market segments?

The financial opportunity within the digital twins market in the healthcare domain has been analyzed across the following segments:

§  Therapeutic Area

§  Cardiovascular Disorders

§  Metabolic Disorders

§  Orthopedic Disorders

§  Other Disorders

§  Type of Digital Twin

§  Process Twins

§  System Twins

§  Whole Body Twins

§  Body Part Twins

§  Area of Application

§  Asset / Process Management

§  Personalized Treatment

§  Surgical Planning

§  Diagnosis

§  Other Applications

§  End Users

§  Pharmaceutical Companies

§  Medical Device Manufacturers

§  Healthcare Providers

§  Patients

§  Other End Users

§  Key Geographical Regions

§  North America

§  Europe

§  Asia

§  Latin America

§  Middle East and North Africa

§  Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.

§  Babylon

§  ExactCure

§  ImmersiveTouch

§  Navv Systems

§  ThoughtWire

§  Unlearn.AI

For additional details, please visit https://www.rootsanalysis.com/reports/digital-twins-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles: 

1.     Flow Cytometry Service Market, 2022-2035

2.     Gene Editing beyond CRISPR Market, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact Information

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Primarily, the key difference between these and conventional buildings is the fact that modular constructs are designed, engineered and manufactured off-site, and later delivered to the intended site of use for final installation. It is worth noting that, in order to ensure that all critical systems are precisely configured, compliant to existing guidelines and fully operational, the modules are tested before shipping.  Even though the concept of using modular manufacturing facilities in the pharmaceutical industry is not new, in recent years, it has witnessed renewed interest from several industry players. The increasing demand for improved processes and production facilities that are capable of handling multiple product types, as well as the shift towards manufacturing of smaller batches of drugs, in case of personalized therapies or candidates targeting rare diseases, are some of the key driving forces for the growing popularity of modular manufacturing plants in the pharmaceutical industry. Modular biomanufacturing includes division of individual production processes, such as fermentation, purification and formulation, into separate modules that can be easily assembled and disassembled, allowing for flexibility and scalability. In addition, modular manufacturing allows the use of smaller-scale production units, which can be more flexible and responsive to dynamic market demands. 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/178/request-sample.html

As indicated earlier, modular construction is a process wherein factory-produced, pre-engineered building units, which are constructed offsite under controlled plant conditions, are assembled on site to construct the final structure. It is worth mentioning that such buildings use the same material and designed according to the same codes and standards established for conventionally built structures. These fundamental building units are called modules. Integrated assemblies are joined together to create facilities of a significant size, housing multiple functions and equipment. The assembled modular building units may form complete rooms, parts of rooms or separate highly serviced units, such as elevators and toilets. There are different types of modules used for construction of buildings. Examples of various modular constructs include 4-sided modules, partially open-sided (corner-supported) modules, mixed modules and planar floor cassettes, modules supported by a primary structural frame, non-load bearing modules, stair modules, skid-mounted process equipment modules, plug and play pods, and balconies and atria.

The modular construction process is believed to reduce the overall time by 50%, as many of the processes are conducted simultaneously.  Although the initial planning required to ensure that all modular units fit together properly is complex, the overall modular construction strategy is simple.

In recent years, the focus of the pharmaceutical industry has shifted from mass production of blockbuster drugs for large patient populations to small batch production of personalized drugs targeting specific subpopulations of patients. Modular facilities were first introduced to the pharmaceutical market at a time when the mass production of tablets and capsules for large patient population was the norm; one of first products to be manufactured in such facilities was statins (prescribed to lower cholesterol).

With the advent of generic copies of billion-dollar blockbuster drugs, targeting major disease indications, drug manufacturers are focusing on developing lower doses of highly potent biopharmaceutical drugs for targeted treatments. This shift has resulted in the segregation of large populations of patients into smaller, more specific sub-groups. Moreover, there is immense pressure on drug manufacturers to market novel drugs as soon as possible, before patent expiry. Increased pressure to expedite time to market, coupled with the need to decrease operating costs and increase manufacturing efficiencies, have amplified the value of smaller production facilities, which are more efficient and flexible. These market developments have made modular facilities more attractive to drug manufacturers today, as these facilities can quickly switch between multiple drugs, enabling formulation and packaging in multiple formats, such as solid, liquid, semi-solid and parenteral dosage forms. With this new set of requirements, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/modular-manufacturing-market/178.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022–2035” report to its list of offerings.

Owing to the recent success and growing pipeline of mRNA-based products in the market, mRNA, as a therapeutic agent, has gained significant traction from the medical community. However, due to challenges, such as high capital requirement, stringent regulations and lack of technical expertise, outsourcing has become a preferred business model and CMOs are upgrading their existing capabilities and service portfolios to meet the increased demand for mRNA-based products.

Key Market Insights

Presently, 30+ companies claim to offer custom synthesis services for mRNA, globally.

Majority of the service providers are mid-sized players (44%), followed by small (35%), large (12%) and very large players (9%). Additionally, more than 25% of the stakeholders were established post 2010. It is also worth mentioning that over 50% of the total players are based in North America, specifically in the US.

More than 40 companies, across the globe, claim to provide contract manufacturing and fill / finish services for mRNA vaccines / therapeutics.

Of the aforementioned players, nearly 85% of the contract manufacturing service providers are based in North America and Europe. Notably, more than 50% of the total players engaged in this space offer services for drug substance (APIs) manufacturing.

Currently, more than 95 mRNA synthesis kits are available in the market.

Close to 70% of the mRNA synthesis kits contain capping enzymes; of these, 96% use T7 RNA polymerase enzyme mix for the synthesis of modified mRNAs. It is worth highlighting that majority (54%) of the kit developers are small players.

More than 170 clinical trials have been registered for the evaluation of mRNA-based therapeutics / vaccines, worldwide.

The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 44%, during the period 2017-2022. Of the total number of trials registered, close to 22% have already been completed, while 46% of the studies are actively recruiting participants.

Partnership activity within this domain has grown at a CAGR of 60%, between 2019 and 2022.

Nearly 34% of the deals were inked in 2021. Majority of the instances captured in the report were manufacturing agreements, representing 22% of the total partnerships. Further, most of the intercontinental deals have been inked by players based in North America.

North America and Europe are anticipated to capture close to 65% of the global market share, by 2035.

The market in Asia Pacific is likely to grow at the highest CAGR during the period 2022-2035. In terms of type of product, drug substance (APIs) is expected to occupy a larger share (70%) of the overall mRNA synthesis and manufacturing service market in 2035.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market/request-sample.html

Key Questions Answered

§  What are the factors driving mRNA synthesis and manufacturing market?

§  How many players are providing services for custom synthesis of mRNAs?

§  How many players are offering mRNA contract manufacturing services for commercial purposes?

§  How many kits are available in the market for the synthesis of mRNA?

§  Which geographical segment has the highest growth rate in mRNA synthesis and manufacturing market?

§  Which segment, in terms of type of product, accounts for the largest mRNA synthesis and manufacturing market share?

§  What is the partnership and collaboration trends in mRNA synthesis and manufacturing domain?

§  Who are the key players in mRNA synthesis and manufacturing market?

The financial opportunity within the mRNA synthesis and manufacturing service market has been analysed across the following segments:

§  Type of Product

§  Drug substances (APIs)

§  Drug products (FDFs)

§  Application Area

§  mRNA-based vaccines

§  mRNA-based therapeutics

§  Therapeutic Area

§  Infectious diseases

§  Oncological disorders

§  Other diseases

§  Key Geographical Regions 

§  North America

§  Europe

§  Asia-Pacific

§  Latin America

§  Middle East and North Africa

§  Rest of the World 

The research also includes detailed profiles of the key players (listed below) engaged in mRNA synthesis and manufacturing domain; each profile features a brief overview of the company, details related to its service portfolio (for mRNA synthesis and contract manufacturing service providers) / product portfolio (mRNA synthesis kit providers), recent developments and an informed future outlook.

§  Aldevron

§  APExBIO

§  Biomay

§  Bio-Synthesis

§  CELLSCRIPT

§  eTheRNA

§  Eurogentec

§  Jena Biosciences

§  New England Biolabs

§  Thermo Fisher Scientific

§  TriLink BioTechnologies

For additional details, please visit 

https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035” report to its list of offerings.

Manufacturing of highly potent compounds is a laborious procedure, plagued with various difficulties, including high capital investment, extensive operational expertise, as well as access to advanced infrastructure and technologies. As a result, outsourcing has become a preferred business model in this domain, providing increased flexibility, reduced costs and timely launch of drugs. Further, to keep up with the evolving client requirements, several contract manufacturing organizations have upgraded their existing capabilities / facilities.

Key Market Insights

More than 140 companies claim to offer highly potent active pharmaceutical ingredients (HPAPI) and cytotoxic drug contract manufacturing services, globally

Majority (44%) of the industry stakeholders are based in Europe, followed by those having headquarters in North America (35%). Further, more than 30% of the service providers claim to have the required capabilities to manufacture both HPAPIs and highly potent finished dosage forms. It is also worth mentioning that over 50% of the players offer contract manufacturing services for HPAPI and cytotoxic drugs across all the three scales of operation.

Around 35% of partnership agreements were inked post 2020

Majority of the agreements related to HPAPI manufacturing were observed to be instances of acquisitions, representing 21% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in Europe.

Over 95 expansion initiatives have been observed since 2018

Around 50% of the initiatives were focused on expanding the existing highly potent compound manufacturing facilities, followed by instances of capacity expansions (27%) and new facility additions (24%). More than 65% of the expansions reported in this domain were local initiatives, followed by international initiatives (33%).

Global installed HPAPI contract manufacturing capacity is currently estimated to be more than 2.5 million liters

The maximum share (83%) of the current installed capacity is expected to be captured by very large players. Moreover, close to 40% of the global, installed manufacturing capacity is available with facilities located in the Europe region.

North America and Europe are anticipated to capture more than 70% of the market share, by 2035

The market in Asia Pacific is likely to grow at a relatively faster pace (12.8%), in the long term. Currently, majority share (62%) of the overall HPAPI and cytotoxic drug contract manufacturing market is captured by HPAPIs; this trend is unlikely to change in the foreseen future as well. Further, in 2035, over 80% of the market share is likely to be captured by highly potent small molecules.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/299/request-sample.html

Key Questions Answered

§  Who are the key players engaged in offering contract manufacturing services for HPAPIs and cytotoxic drugs?

§  What are the current opportunities within the HPAPI and cytotoxic drug market?

§  What is the relative competitiveness of HPAPI and cytotoxic drug contract manufacturers?

§  What types of partnership models are commonly adopted by stakeholders in this industry?

§  What are the different types of expansion initiatives being undertaken by HPAPI and cytotoxic drug contract manufacturers?

§  What are the key challenges faced by HPAPI and cytotoxic drug contract manufacturers?

§  What are the key market trends and driving factors that are likely to impact this market?

§  How is the revenue generation potential associated with HPAPI and cytotoxic drug manufacturing market likely to evolve in the coming years?

The financial opportunity within the HPAPI and cytotoxic drug manufacturing market has been analyzed across the following segments:

§  Type of Product

§  Highly Potent Active Pharmaceutical Ingredient

§  Highly Potent Finished Dosage Form

§  Company Size

§  Small

§  Mid-sized

§  Large

§  Very Large

§  Scale of Operation

§  Preclinical

§  Clinical

§  Commercial

§  Type of Molecule

§  Small Molecules

§  Biologics

§  Type of Highly Potent Finished Dosage Form

§  Injectables

§  Oral Solids

§  Creams

§  Others

§  Key Geographical Regions 

§  North America (US, Canada and Mexico)

§  Europe (UK, Italy, Germany, France, Spain and Rest of Europe)

§  Asia-Pacific (China, India and Rest of Asia-Pacific)

§  Rest of the World 

The report also features inputs from eminent industry stakeholders, according to whom, continuous growth of the oncological therapeutics pipeline and the increasing preference for outsourcing is likely to drive the growth of the overall HPAPI and cytotoxic drug manufacturing market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:

§  Justin Mason-Home (Owner and Director, HPAPI Project Service)

§  Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)

§  Scott Patterson (Vice President Pharma/Bio Technical Support, ILC Dover)

§  Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent)

§  Roberto Margarita (Business Development Director, CordenPharma)

§  Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)

§  Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora Research (Acquired by Eurofins))

§  Mark Wright (Ex-Site Head, Grangemouth, Piramal)

§  Allison Vavala (Ex-Senior Manager, Business Development, Helsinn)

§  Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma)

§  Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial performance (if available), recent developments and an informed future outlook.

§  AbbVie

§  Abzena

§  Aenova

§  Cambrex

§  CARBOGEN AMCIS

§  Catalent

§  Hovione

§  Intas Pharmaceuticals

§  Lonza

§  Pfizer CentreOne

§  Piramal Pharma Solutions

§  Scinopharm

§  STA Pharmaceutical (a WuXi AppTec company)

§  Syngene

§  Teva API

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.       Biopharmaceutical Contract Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035

2.       ADC Contract Manufacturing Market (5th Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035” report to its list of offerings.

Manufacturing of highly potent compounds is a laborious procedure, plagued with various difficulties, including high capital investment, extensive operational expertise, as well as access to advanced infrastructure and technologies. As a result, outsourcing has become a preferred business model in this domain, providing increased flexibility, reduced costs and timely launch of drugs. Further, to keep up with the evolving client requirements, several contract manufacturing organizations have upgraded their existing capabilities / facilities.

Key Market Insights

More than 140 companies claim to offer highly potent active pharmaceutical ingredients (HPAPI) and cytotoxic drug contract manufacturing services, globally

Majority (44%) of the industry stakeholders are based in Europe, followed by those having headquarters in North America (35%). Further, more than 30% of the service providers claim to have the required capabilities to manufacture both HPAPIs and highly potent finished dosage forms. It is also worth mentioning that over 50% of the players offer contract manufacturing services for HPAPI and cytotoxic drugs across all the three scales of operation.

Around 35% of partnership agreements were inked post 2020

Majority of the agreements related to HPAPI manufacturing were observed to be instances of acquisitions, representing 21% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in Europe.

Over 95 expansion initiatives have been observed since 2018

Around 50% of the initiatives were focused on expanding the existing highly potent compound manufacturing facilities, followed by instances of capacity expansions (27%) and new facility additions (24%). More than 65% of the expansions reported in this domain were local initiatives, followed by international initiatives (33%).

Global installed HPAPI contract manufacturing capacity is currently estimated to be more than 2.5 million liters

The maximum share (83%) of the current installed capacity is expected to be captured by very large players. Moreover, close to 40% of the global, installed manufacturing capacity is available with facilities located in the Europe region.

North America and Europe are anticipated to capture more than 70% of the market share, by 2035

The market in Asia Pacific is likely to grow at a relatively faster pace (12.8%), in the long term. Currently, majority share (62%) of the overall HPAPI and cytotoxic drug contract manufacturing market is captured by HPAPIs; this trend is unlikely to change in the foreseen future as well. Further, in 2035, over 80% of the market share is likely to be captured by highly potent small molecules.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/299/request-sample.html

Key Questions Answered

§  Who are the key players engaged in offering contract manufacturing services for HPAPIs and cytotoxic drugs?

§  What are the current opportunities within the HPAPI and cytotoxic drug market?

§  What is the relative competitiveness of HPAPI and cytotoxic drug contract manufacturers?

§  What types of partnership models are commonly adopted by stakeholders in this industry?

§  What are the different types of expansion initiatives being undertaken by HPAPI and cytotoxic drug contract manufacturers?

§  What are the key challenges faced by HPAPI and cytotoxic drug contract manufacturers?

§  What are the key market trends and driving factors that are likely to impact this market?

§  How is the revenue generation potential associated with HPAPI and cytotoxic drug manufacturing market likely to evolve in the coming years?

The financial opportunity within the HPAPI and cytotoxic drug manufacturing market has been analyzed across the following segments:

§  Type of Product

§  Highly Potent Active Pharmaceutical Ingredient

§  Highly Potent Finished Dosage Form

§  Company Size

§  Small

§  Mid-sized

§  Large

§  Very Large

§  Scale of Operation

§  Preclinical

§  Clinical

§  Commercial

§  Type of Molecule

§  Small Molecules

§  Biologics

§  Type of Highly Potent Finished Dosage Form

§  Injectables

§  Oral Solids

§  Creams

§  Others

§  Key Geographical Regions 

§  North America (US, Canada and Mexico)

§  Europe (UK, Italy, Germany, France, Spain and Rest of Europe)

§  Asia-Pacific (China, India and Rest of Asia-Pacific)

§  Rest of the World 

The report also features inputs from eminent industry stakeholders, according to whom, continuous growth of the oncological therapeutics pipeline and the increasing preference for outsourcing is likely to drive the growth of the overall HPAPI and cytotoxic drug manufacturing market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:

§  Justin Mason-Home (Owner and Director, HPAPI Project Service)

§  Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)

§  Scott Patterson (Vice President Pharma/Bio Technical Support, ILC Dover)

§  Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent)

§  Roberto Margarita (Business Development Director, CordenPharma)

§  Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)

§  Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora Research (Acquired by Eurofins))

§  Mark Wright (Ex-Site Head, Grangemouth, Piramal)

§  Allison Vavala (Ex-Senior Manager, Business Development, Helsinn)

§  Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma)

§  Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial performance (if available), recent developments and an informed future outlook.

§  AbbVie

§  Abzena

§  Aenova

§  Cambrex

§  CARBOGEN AMCIS

§  Catalent

§  Hovione

§  Intas Pharmaceuticals

§  Lonza

§  Pfizer CentreOne

§  Piramal Pharma Solutions

§  Scinopharm

§  STA Pharmaceutical (a WuXi AppTec company)

§  Syngene

§  Teva API

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.       Biopharmaceutical Contract Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035

2.       ADC Contract Manufacturing Market (5th Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Roots Analysis has announced the addition of “HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035” report to its list of offerings.

Manufacturing of highly potent compounds is a laborious procedure, plagued with various difficulties, including high capital investment, extensive operational expertise, as well as access to advanced infrastructure and technologies. As a result, outsourcing has become a preferred business model in this domain, providing increased flexibility, reduced costs and timely launch of drugs. Further, to keep up with the evolving client requirements, several contract manufacturing organizations have upgraded their existing capabilities / facilities.

Key Market Insights

More than 140 companies claim to offer highly potent active pharmaceutical ingredients (HPAPI) and cytotoxic drug contract manufacturing services, globally

Majority (44%) of the industry stakeholders are based in Europe, followed by those having headquarters in North America (35%). Further, more than 30% of the service providers claim to have the required capabilities to manufacture both HPAPIs and highly potent finished dosage forms. It is also worth mentioning that over 50% of the players offer contract manufacturing services for HPAPI and cytotoxic drugs across all the three scales of operation.

Around 35% of partnership agreements were inked post 2020

Majority of the agreements related to HPAPI manufacturing were observed to be instances of acquisitions, representing 21% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in Europe.

Over 95 expansion initiatives have been observed since 2018

Around 50% of the initiatives were focused on expanding the existing highly potent compound manufacturing facilities, followed by instances of capacity expansions (27%) and new facility additions (24%). More than 65% of the expansions reported in this domain were local initiatives, followed by international initiatives (33%).

Global installed HPAPI contract manufacturing capacity is currently estimated to be more than 2.5 million liters

The maximum share (83%) of the current installed capacity is expected to be captured by very large players. Moreover, close to 40% of the global, installed manufacturing capacity is available with facilities located in the Europe region.

North America and Europe are anticipated to capture more than 70% of the market share, by 2035

The market in Asia Pacific is likely to grow at a relatively faster pace (12.8%), in the long term. Currently, majority share (62%) of the overall HPAPI and cytotoxic drug contract manufacturing market is captured by HPAPIs; this trend is unlikely to change in the foreseen future as well. Further, in 2035, over 80% of the market share is likely to be captured by highly potent small molecules.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/299/request-sample.html

Key Questions Answered

§  Who are the key players engaged in offering contract manufacturing services for HPAPIs and cytotoxic drugs?

§  What are the current opportunities within the HPAPI and cytotoxic drug market?

§  What is the relative competitiveness of HPAPI and cytotoxic drug contract manufacturers?

§  What types of partnership models are commonly adopted by stakeholders in this industry?

§  What are the different types of expansion initiatives being undertaken by HPAPI and cytotoxic drug contract manufacturers?

§  What are the key challenges faced by HPAPI and cytotoxic drug contract manufacturers?

§  What are the key market trends and driving factors that are likely to impact this market?

§  How is the revenue generation potential associated with HPAPI and cytotoxic drug manufacturing market likely to evolve in the coming years?

The financial opportunity within the HPAPI and cytotoxic drug manufacturing market has been analyzed across the following segments:

§  Type of Product

§  Highly Potent Active Pharmaceutical Ingredient

§  Highly Potent Finished Dosage Form

§  Company Size

§  Small

§  Mid-sized

§  Large

§  Very Large

§  Scale of Operation

§  Preclinical

§  Clinical

§  Commercial

§  Type of Molecule

§  Small Molecules

§  Biologics

§  Type of Highly Potent Finished Dosage Form

§  Injectables

§  Oral Solids

§  Creams

§  Others

§  Key Geographical Regions 

§  North America (US, Canada and Mexico)

§  Europe (UK, Italy, Germany, France, Spain and Rest of Europe)

§  Asia-Pacific (China, India and Rest of Asia-Pacific)

§  Rest of the World 

The report also features inputs from eminent industry stakeholders, according to whom, continuous growth of the oncological therapeutics pipeline and the increasing preference for outsourcing is likely to drive the growth of the overall HPAPI and cytotoxic drug manufacturing market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:

§  Justin Mason-Home (Owner and Director, HPAPI Project Service)

§  Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)

§  Scott Patterson (Vice President Pharma/Bio Technical Support, ILC Dover)

§  Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent)

§  Roberto Margarita (Business Development Director, CordenPharma)

§  Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)

§  Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora Research (Acquired by Eurofins))

§  Mark Wright (Ex-Site Head, Grangemouth, Piramal)

§  Allison Vavala (Ex-Senior Manager, Business Development, Helsinn)

§  Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma)

§  Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial performance (if available), recent developments and an informed future outlook.

§  AbbVie

§  Abzena

§  Aenova

§  Cambrex

§  CARBOGEN AMCIS

§  Catalent

§  Hovione

§  Intas Pharmaceuticals

§  Lonza